<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998073</article-id><article-id pub-id-type="pmc">PMC11860322</article-id>
<article-id pub-id-type="doi">10.3390/toxins17020056</article-id><article-id pub-id-type="publisher-id">toxins-17-00056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Anthrax: Transmission, Pathogenesis, Prevention and Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sangwan</surname><given-names>Nitika</given-names></name><xref rid="af1-toxins-17-00056" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Gangwal</surname><given-names>Aakriti</given-names></name><xref rid="af2-toxins-17-00056" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Preksha</given-names></name><xref rid="af3-toxins-17-00056" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Langtso</surname><given-names>Chokey</given-names></name><xref rid="af3-toxins-17-00056" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>Shruti</given-names></name><xref rid="af3-toxins-17-00056" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7124-393X</contrib-id><name><surname>Dhawan</surname><given-names>Uma</given-names></name><xref rid="af1-toxins-17-00056" ref-type="aff">1</xref><xref rid="c1-toxins-17-00056" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9868-2449</contrib-id><name><surname>Baweja</surname><given-names>Renu</given-names></name><xref rid="af4-toxins-17-00056" ref-type="aff">4</xref><xref rid="c1-toxins-17-00056" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3902-4355</contrib-id><name><surname>Singh</surname><given-names>Yogendra</given-names></name><xref rid="af3-toxins-17-00056" ref-type="aff">3</xref></contrib></contrib-group><aff id="af1-toxins-17-00056"><label>1</label>Department of Biomedical Science, Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi 110075, India</aff><aff id="af2-toxins-17-00056"><label>2</label>Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 94305, USA</aff><aff id="af3-toxins-17-00056"><label>3</label>Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India</aff><aff id="af4-toxins-17-00056"><label>4</label>Department of Biochemistry, Shivaji College, University of Delhi, Delhi 110027, India</aff><author-notes><corresp id="c1-toxins-17-00056"><label>*</label>Correspondence: <email>uma.dhawan@bcas.du.ac.in</email> (U.D.); <email>renubaweja@shivaji.du.ac.in</email> (R.B.)</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>56</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic toggle="yes">Bacillus anthracis</italic> is a deadly pathogen that under unfavourable conditions forms highly resistant spores which enable them to survive for a long period of time. Spores of <italic toggle="yes">B. anthracis</italic> are transmitted through the contaminated soil or animal products and enter to the host through the skin, lungs or oral route and can cause cutaneous, injection, inhalation and gastrointestinal anthrax, respectively. The disease is caused by the toxin which is produced by them once they germinate within the host cell. Anthrax toxin is the major virulence factor which has the ability to kill the host cell. The role of protein kinases and phosphatases of <italic toggle="yes">B. anthracis</italic> in toxin production and other virulence related properties have also been reported. There are two vaccines, BioThrax and CYFENDUS<sup>TM</sup>, which are approved by the FDA-USA to prevent anthrax disease. Recently, anthrax toxin has also been shown to be a potential candidate for cancer therapeutics. Through present review, we aim to provide insights into sporulation, transmission and pathogenesis of <italic toggle="yes">B. anthracis</italic> as well as the current state of its prevention, treatment, vaccines and possible therapeutic uses in cancer.</p></abstract><kwd-group><kwd>sporulation</kwd><kwd>germination</kwd><kwd>bacterial toxin</kwd><kwd>pathogenesis</kwd><kwd>anthrax vaccine</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta><notes notes-type="Key Contribution"><title>Key Contribution</title><p>We describe the anthrax disease and the role of toxins and other components in pathogenesis of <italic toggle="yes">Bacillus anthracis</italic>. The manuscript contains the recent developments in anthrax vaccine research and role of phosphorylation in virulence of <italic toggle="yes">B. anthracis</italic>.</p></notes></front><body><sec sec-type="intro" id="sec1-toxins-17-00056"><title>1. Introduction</title><p>The life cycle of <italic toggle="yes">Bacillus anthracis</italic> is centered around two distinct phases, namely sporulation and germination, which are well-explored processes. In brief, sporulation is a multi-step process involving asymmetric septation of the vegetative bacillus resulting in the formation of two compartments, the mother cell and the forespore. Following this, the forespore remains engulfed by the mother cell and once spores mature, they are released outside the environment (<xref rid="toxins-17-00056-f001" ref-type="fig">Figure 1</xref>). These spores, being highly resistant, can survive and remain dormant for years until favourable conditions resume [<xref rid="B1-toxins-17-00056" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00056" ref-type="bibr">2</xref>]. Once transmitted, these deadly spores can enter the host and are responsible for causing anthrax. The pathogenesis and survival of <italic toggle="yes">B. anthracis</italic> is a well-studied phenomenon. Lately, it has been reported that protein phosphorylation has a significant role in the pathogenesis of <italic toggle="yes">B. anthracis</italic> by modulating various cellular processes essential for its survival, virulence and ability to evade host immune responses [<xref rid="B3-toxins-17-00056" ref-type="bibr">3</xref>,<xref rid="B4-toxins-17-00056" ref-type="bibr">4</xref>]. Targeting protein phosphorylation pathways in <italic toggle="yes">B. anthracis</italic> offers a promising approach for developing new drugs against this deadly pathogen. Although there are advancements in the treatment of anthrax, the effectiveness of existing antibiotics, small-molecule inhibitors and vaccines depends upon the timing of their administration. The gaps pertaining to the spore-specific therapies, toxin-mediated damage and late-stage interventions persist and continued research into anthrax pathogenesis and host&#x02013;pathogen interactions is critical in ensuring better preparedness and more effective management of anthrax.</p></sec><sec id="sec2-toxins-17-00056"><title>2. Sporulation and Germination of <italic toggle="yes">Bacillus anthracis</italic> Spores</title><p>The formation of spores is the crucial aspect of the life cycle of <italic toggle="yes">B. anthracis</italic>, which enables its survival in adverse environmental conditions. Their spores can survive and remain dormant under extreme environmental stresses including nutrient deprivation, heat, UV radiation, acid, alkali and other chemical agents [<xref rid="B1-toxins-17-00056" ref-type="bibr">1</xref>] and are also easily transmitted through air, water or soil. Once transmitted, these spores can come into contact with their potential host (human or animal), wherein they germinate and eventually cause infection. Importantly, <italic toggle="yes">B. anthracis</italic> spores are proven to be a potential bioweapon, which is of constant concern worldwide [<xref rid="B2-toxins-17-00056" ref-type="bibr">2</xref>,<xref rid="B5-toxins-17-00056" ref-type="bibr">5</xref>].</p><p>The formation of spores through sporulation and the conversion of spores to vegetative cells through germination are the key steps in the life cycle of <italic toggle="yes">B. anthracis</italic> [<xref rid="B6-toxins-17-00056" ref-type="bibr">6</xref>]. The spore formation takes place in a number of stages as follows: stage I is the initiation stage, wherein DNA is present as an axial filament; this is followed by the formation of septum and asymmetric cell formation of the mother cell and forespore in stage II. The forespore is engulfed by the mother cell in stage III, followed by the formation of cortex in stage IV. The synthesis of spore coat proteins, dipicolinic acid (DPA) and uptake of calcium in the spore core commences in stage V. In stage VI, spores become mature and retractile and are finally released from the mother cell in stage VII (<xref rid="toxins-17-00056-f002" ref-type="fig">Figure 2</xref>).</p><p>The phenomenon of sporulation is under the tight control of five sigma factors which regulate the cells at both the transcriptional and physiological level [<xref rid="B7-toxins-17-00056" ref-type="bibr">7</xref>]. These sigma factors, which are sequentially expressed, temporally regulate the expression of mRNAs to ensure the compartment-specific expression of genes required for spore formation [<xref rid="B8-toxins-17-00056" ref-type="bibr">8</xref>]. Firstly, &#x003c3;<sup>H</sup> is expressed towards the end of the exponential and beginning of the stationary phase of the growth to initiate the sporulation process. It also directs the expression of the genes needed for the activation of subsequent sigma factors including &#x003c3;<sup>F</sup> and &#x003c3;<sup>E</sup>, which are early forespore-specific and early mother cell-specific sigma factors. &#x003c3;<sup>F</sup> not only helps in forespore development but also directs the formation of the spore core. &#x003c3;<sup>E</sup> controls the expression of mRNAs required for the mother cell engulfment of the forespore [<xref rid="B9-toxins-17-00056" ref-type="bibr">9</xref>]. Following this is spore maturation, wherein the formation of spore cortex and coat proteins takes place under the control of &#x003c3;<sup>G</sup>, and it has been reported that the &#x0201c;Fin&#x0201d; protein is required for efficient switching from &#x003c3;<sup>F</sup> to &#x003c3;<sup>G</sup> [<xref rid="B10-toxins-17-00056" ref-type="bibr">10</xref>]. Last, there is an expression of &#x003c3;<sup>K</sup>, which finalizes the coat formation, and ultimately the mature spores from the mother cell. In addition to its role in sporulation, &#x003c3;<sup>H</sup> is also shown to be a key independent player for regulating the expression of anthrax toxin [<xref rid="B11-toxins-17-00056" ref-type="bibr">11</xref>].</p><p>Interestingly, there are many other proteins which affect the formation of spores. One such protein is spoVG. The sporulation of the &#x00394;<italic toggle="yes">spoVG</italic> mutant of <italic toggle="yes">B. anthracis</italic> vaccine strain is affected and blocked after stage I, leading to the absence of compartmentalization between MC and FS due to defects in the formation of the asymmetric septum [<xref rid="B12-toxins-17-00056" ref-type="bibr">12</xref>]. Similarly, the Spo0E family of proteins is also shown to negatively regulate the sporulation pathway of <italic toggle="yes">B. anthracis</italic> by dephosphorylating the Spo0A response regulator, a master response regulator of initiation of sporulation [<xref rid="B13-toxins-17-00056" ref-type="bibr">13</xref>]. Furthermore, multiple genes have been shown to affect the sporulation and germination of <italic toggle="yes">B. anthracis</italic>. Liszewski Zilla M et al. (2015) studied the role of LCP (LytR-CpsA-Psr) enzymes in growth and sporulation of <italic toggle="yes">B. anthracis</italic> [<xref rid="B14-toxins-17-00056" ref-type="bibr">14</xref>]. LCP enzymes are universal enzymes which transfer undecaprenyl-phosphate polymers to peptidoglycan in Gram-positive bacteria and in <italic toggle="yes">B. anthracis</italic>; they are six in numbers namely LcpB1-4, LcpC and LcpD. The study showed the significant role of LcpB1, LcpB2 and LcpB4 in the sporulation of <italic toggle="yes">B. anthracis</italic> with a substantial decrease in sporulation efficiency in strains lacking these three enzymes. In another study, the role of the McsB and ClpC proteins of the clpC operon was demonstrated in the sporulation and germination of <italic toggle="yes">B. anthracis</italic>. Reduced sporulation efficiency by 40% and 60%, respectively, was observed in <italic toggle="yes">&#x00394;clpC</italic> and <italic toggle="yes">&#x00394;mcsB</italic> even after 144 h of the growth under suitable growth conditions. The spores formed were defective with respect to their coat layer formation, resulting in a drastic reduction of their germination with efficiency of 40% in case of <italic toggle="yes">&#x00394;mcsB</italic> and 10% in <italic toggle="yes">&#x00394;clpC</italic> [<xref rid="B15-toxins-17-00056" ref-type="bibr">15</xref>]. PrpN, a serine/threonine protein phosphatase of <italic toggle="yes">B. anthracis,</italic> was also reported to play an indispensable role in its sporulation and germination. Sporulation was delayed in the <italic toggle="yes">&#x00394;prpN</italic> strain of <italic toggle="yes">B. anthracis</italic>, with a sporulation efficiency of only 0.01% as compared to the wild-type strain. These spores were also structurally abnormal with the missing spore layers [<xref rid="B16-toxins-17-00056" ref-type="bibr">16</xref>].</p><p>The spores of <italic toggle="yes">bacillus</italic> species may remain quiescent for many years and can resist a wide range of stresses [<xref rid="B1-toxins-17-00056" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00056" ref-type="bibr">2</xref>,<xref rid="B17-toxins-17-00056" ref-type="bibr">17</xref>] due to their unique protein composition and structural and physical features (<xref rid="toxins-17-00056-f003" ref-type="fig">Figure 3</xref>). Proteomic studies of the spores have revealed the presence of 500&#x02013;800 numbers of proteins depending upon the strain and stage (dormant or germinating spores) of the bacillus and also the experimental methods used for the analysis [<xref rid="B18-toxins-17-00056" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00056" ref-type="bibr">19</xref>,<xref rid="B20-toxins-17-00056" ref-type="bibr">20</xref>]. Structurally, the spore cytoplasm (core) is poorly hydrated and contains high concentrations of small acid-soluble proteins (SASPs). These SASPs, along with high levels of calcium-dipicolinic acid (Ca-DPA) and other ions, are responsible for their resistance to heat and ultraviolet radiation [<xref rid="B21-toxins-17-00056" ref-type="bibr">21</xref>,<xref rid="B22-toxins-17-00056" ref-type="bibr">22</xref>]. The core also comprises DnaK and GroE, heat shock proteins, which become activated during stress and aid in protein folding during germination. The RecA core protein helps to repair DNA damages that occur during spore dormancy. The dehydrated state of the core is also governed by the core membrane and a surrounding peptidoglycan layer, which restrict the entry and exit of water and other solutes [<xref rid="B2-toxins-17-00056" ref-type="bibr">2</xref>]. These dehydrated conditions help to maintain the spore dormancy. Further, the cortex hydrolases such as SleB and CwlJ are important for the degradation of the cortex during spore germination [<xref rid="B23-toxins-17-00056" ref-type="bibr">23</xref>]. The cortex is surrounded by a coat which contains several proteins and has been shown to confer resistance to several degradative enzymes like proteases and lipases and other sporicidal substances [<xref rid="B24-toxins-17-00056" ref-type="bibr">24</xref>]. The coat layer also serves as a barrier by protecting the spore from toxic molecules [<xref rid="B22-toxins-17-00056" ref-type="bibr">22</xref>]. For example, cot&#x003b1;, an outer spore coat protein of <italic toggle="yes">B. anthracis</italic>, provides resistance to phenol (10%), chloroform (10%) and hypochlorite (4%) [<xref rid="B25-toxins-17-00056" ref-type="bibr">25</xref>]. However, it is not impermeable, as it provides access to germinants to the receptors present on the inner forespore membrane and hence has a role in germination [<xref rid="B26-toxins-17-00056" ref-type="bibr">26</xref>]. The coat layer is surrounded by the exosporium, which is made up of a basal layer and an external hair-like structure of glycoprotein called BclA [<xref rid="B2-toxins-17-00056" ref-type="bibr">2</xref>,<xref rid="B8-toxins-17-00056" ref-type="bibr">8</xref>,<xref rid="B22-toxins-17-00056" ref-type="bibr">22</xref>]. This is the outermost layer of the spore and may play a major role in spore adherence and its aggregation by affecting their electrostatic properties, which determines their dispersal and infectivity [<xref rid="B22-toxins-17-00056" ref-type="bibr">22</xref>]. Besides the main structural components described above, the spore core is also surrounded by two membranes. The inner spore membrane surrounds the spore core and is believed to be the house of germinant receptors responsible for sensing the number of small molecules that act as triggering agents of germination [<xref rid="B21-toxins-17-00056" ref-type="bibr">21</xref>]. The outer spore membrane is thought to contain the cortical degradative enzyme SleB and its stabilizing protein YpeB, but their locations are not yet certain and it has been suggested that these enzymes are present in the spore coats [<xref rid="B27-toxins-17-00056" ref-type="bibr">27</xref>].</p><p>Spores can remain in a dormant state for years. Under suitable environmental conditions and in the presence of germinants, they lose their dormancy and germinate. These germinants are small biomolecules such as sugars, purine nucleotides, amino acids or their combinations [<xref rid="B29-toxins-17-00056" ref-type="bibr">29</xref>]. As soon as spores are mixed with germinants, germination begins due to the activation of germinant receptors [<xref rid="B21-toxins-17-00056" ref-type="bibr">21</xref>,<xref rid="B30-toxins-17-00056" ref-type="bibr">30</xref>,<xref rid="B31-toxins-17-00056" ref-type="bibr">31</xref>]. In <italic toggle="yes">B. anthracis</italic>, there are five functional germinant receptors encoded by the tricistronic operon. Four of these, namely <italic toggle="yes">gerH</italic>, <italic toggle="yes">gerK</italic>, <italic toggle="yes">gerL</italic> and <italic toggle="yes">gerH</italic>, are located on the chromosomal DNA, and the fifth one, namely <italic toggle="yes">gerX</italic>, is located on plasmid pXO1. Further, the access of a germinant to its receptor is also reported to be facilitated by specific proteins. GerP protein is shown to be required for rapid germination of <italic toggle="yes">B. anthracis</italic> spores, probably by increasing the access of germinants to their receptors [<xref rid="B32-toxins-17-00056" ref-type="bibr">32</xref>]. Once receptors recognize their specific germinants, a series of events is initiated. Firstly, the spore core releases monovalent ions, including K<sup>+</sup>, Na<sup>+</sup> and H<sup>+</sup>, which results in the increase in the pH of the spore core from slightly acidic to basic [<xref rid="B33-toxins-17-00056" ref-type="bibr">33</xref>]. The core becomes rehydrated by releasing Ca-DPA and its associated divalent ions. The release of Ca-DPA is thought to be governed by the SpoVA protein associated-channels of the spore&#x02019;s inner membrane [<xref rid="B34-toxins-17-00056" ref-type="bibr">34</xref>]. This completes the stage I of the spore germination. During stage II, the peptidoglycan (PG) layer of the spore cortex becomes degraded by cortex-lytic-enzymes (CLEs) via the modification of its muramic acid-&#x003b4;-lactum residues. The two major CLEs of <italic toggle="yes">Bacillus</italic> species are CwlJ and SleB, which, when acting together or alone, hydrolyse the spore cortex PG layer [<xref rid="B35-toxins-17-00056" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00056" ref-type="bibr">36</xref>]. The removal of the PG layer causes further uptake of water, which enhances core rehydration resulting in the spore core with 80% wet weight as water [<xref rid="B37-toxins-17-00056" ref-type="bibr">37</xref>]. The increase in water content helps in enhancing protein mobility in the core and degradation of SASPs to release amino acids. These SASPs constitute around 10% of the spore core proteins, in which they associate with DNA (&#x003b1;/&#x003b2;) and protect it from heat and oxidizing agents [<xref rid="B37-toxins-17-00056" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00056" ref-type="bibr">38</xref>]. The degradation of SASPs is essential to provide access for proteins to core DNA for transcription during the spore outgrowth. The increase in water content of the spore core helps to activate the metabolic enzymes of the spore core, resulting in synthesis of macromolecules required for vegetative cell formation. Germination is followed by the spore outgrowth, in which spores develop into vegetative cells which are capable of normal growth and division (<xref rid="toxins-17-00056-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B33-toxins-17-00056" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00056" ref-type="bibr">36</xref>,<xref rid="B38-toxins-17-00056" ref-type="bibr">38</xref>].</p></sec><sec id="sec3-toxins-17-00056"><title>3. Transmission of <italic toggle="yes">Bacillus anthracis</italic> Spores</title><p>In order to effectively manage and control anthrax outbreaks, it is important to understand the transmission of <italic toggle="yes">B. anthracis</italic> spores [<xref rid="B39-toxins-17-00056" ref-type="bibr">39</xref>]. Being a potential bioweapon, knowledge of its transmission further aids in designing strategies for biodefense. The transmission of spores primarily occurs via contaminated soil, animal products or carcasses of infected animals through various routes such as cutaneous contact, ingestion or inhalation resulting in cutaneous, gastrointestinal or inhalation anthrax, respectively [<xref rid="B39-toxins-17-00056" ref-type="bibr">39</xref>].</p><sec id="sec3dot1-toxins-17-00056"><title>3.1. Cutaneous Anthrax</title><p>In cutaneous anthrax, spores enter through skin abrasions, and therefore, anthrax is generally associated with occupational contact. Butchers, wool processors and animal handlers are at higher risk [<xref rid="B40-toxins-17-00056" ref-type="bibr">40</xref>]. It can also be transmitted by non-biting flies which can deposit spores or bacilli on abrasions or by biting flies which can transfer it directly to blood through open wounds. The spores could be picked up from the carcass when they are present on their body and also in their crops or intestines [<xref rid="B41-toxins-17-00056" ref-type="bibr">41</xref>]. Cutaneous anthrax accounts for more than 90% of cases of anthrax infection. Its incubation period varies from 2&#x02013;6 days, after which there is a development of skin lesions, which are usually painless and pruritic papules. In 2&#x02013;3 days, the lesion matures, undergoes necrosis and finally forms a characteristic black dead tissue surrounded by edema [<xref rid="B42-toxins-17-00056" ref-type="bibr">42</xref>,<xref rid="B43-toxins-17-00056" ref-type="bibr">43</xref>]. The fatality rate is 20% without antibiotics and &#x0003c;1% with antibiotic treatment [<xref rid="B44-toxins-17-00056" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot2-toxins-17-00056"><title>3.2. Gastrointestinal Anthrax</title><p>It mainly occurs in animals grazing on contaminated pastures and in humans by ingesting inadequately cooked contaminated food products. The incubation period of the bacilli ranges from 3&#x02013;7 days, and the lesions can develop at any location throughout the gastrointestinal lining. The initial symptoms include fever, vomiting, nausea, diarrhoea and abdominal pain. With further progress in infection, severe symptoms are observed including acute&#x02013;unbearable abdominal pain, bloody diarrhoea, septicemia shock and eventually death. Unlike cutaneous anthrax, its mortality rate is higher with up to 60%, if untreated and around 25% with proper treatment [<xref rid="B42-toxins-17-00056" ref-type="bibr">42</xref>,<xref rid="B43-toxins-17-00056" ref-type="bibr">43</xref>,<xref rid="B45-toxins-17-00056" ref-type="bibr">45</xref>].</p></sec><sec id="sec3dot3-toxins-17-00056"><title>3.3. Inhalation Anthrax</title><p>With the highest rate of mortality at 45% with antibiotic and &#x0003e;95% without antibiotic treatment, it is the most dangerous form of anthrax [<xref rid="B40-toxins-17-00056" ref-type="bibr">40</xref>]. It occurs due to the inhalation of pathogenic spores. Within the lungs, these spores become engulfed by the immune cells and then are transported to the lymph nodes. The toxins produced by the bacteria in the lymph node disrupt their integrity and enter the blood, causing bacteremia and the death of the host. The appearance of the symptoms is biphasic, with initial symptoms appearing 1&#x02013;7 days after infection, and are mainly due to the infection in the upper respiratory tract [<xref rid="B39-toxins-17-00056" ref-type="bibr">39</xref>]. The symptoms include fever, chills, fatigue and non-productive cough. This is followed by more severe symptoms of chest pain, breathing difficulties and high fever. Without medication, the condition worsens, resulting in septicemia, edema and fatal shock.</p></sec><sec id="sec3dot4-toxins-17-00056"><title>3.4. Injection Anthrax</title><p>It is the rarest form of anthrax, which is caused by the entry of <italic toggle="yes">B. anthracis</italic> spores through intravenous, subcutaneous or intramuscular injection of contaminated drugs. The infection causes severe edema at the injection site, resulting in abscess or necrotizing fasciitis [<xref rid="B46-toxins-17-00056" ref-type="bibr">46</xref>]. To date, three outbreaks of injection anthrax have been reported among heroin users in Europe, with a mortality rate of up to 35% [<xref rid="B47-toxins-17-00056" ref-type="bibr">47</xref>]. Besides antibiotic treatment, surgical removal of the infected region is necessary to treat the infection.</p><p>Meningitis due to <italic toggle="yes">B. anthracis</italic> infection is a rare but fatal form of anthrax. The anthrax bacilli can enter through the skin or the oral or respiratory route, spread via blood or lymph to the central nervous system after crossing the blood&#x02013;brain barrier and cause meningitis [<xref rid="B48-toxins-17-00056" ref-type="bibr">48</xref>].</p></sec></sec><sec id="sec4-toxins-17-00056"><title>4. Virulence Factors</title><p>Bacterial pathogens are known to have multiple virulence factors comprising proteins, carbohydrates, lipids, etc. Some bacterial toxins comprise two components, one having enzymatic activity (A) and other having the ability to bind receptors (B). Therefore, these toxins are also known as AB toxins. The receptor-binding component binds to the receptor and delivers an enzymatic moiety to the cytosol, which can cause deregulation of cellular metabolism, leading to cell death. Bacterial toxins are known to exhibit DNAse, RNAse, ADP ribosylation and other enzymatic activities. The arrangement of enzymatic component and receptor-binding component varies among various toxins. While in some bacterial protein toxins, both A and B components are present on the same polypeptide, in many toxins, these are present on different polypeptide chains. Different bipartite bacterial toxins are released by <italic toggle="yes">Pseudomonas</italic>, <italic toggle="yes">Streptococcus</italic>, <italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Bacillus</italic>, etc. [<xref rid="B49-toxins-17-00056" ref-type="bibr">49</xref>]. </p><p><italic toggle="yes">B. anthracis</italic> virulence factors comprise a tripartite toxin and an antiphagocytic polypeptide capsule. The genetic foundation of these virulence factors lies within pXO1 and pXO2 plasmids. The anthrax toxins, namely Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF), are encoded by pXO1, while pXO2 encodes the capsule that prevents phagocytosis [<xref rid="B50-toxins-17-00056" ref-type="bibr">50</xref>] (<xref rid="toxins-17-00056-f005" ref-type="fig">Figure 5</xref>).</p><p>These virulence factors allow the bacteria to enter into the host cell, escape the immune system and responses and induce severe systemic infections that can be fatal if untreated [<xref rid="B50-toxins-17-00056" ref-type="bibr">50</xref>,<xref rid="B51-toxins-17-00056" ref-type="bibr">51</xref>]. The pathogenicity of <italic toggle="yes">B. anthracis</italic> hinges on its ability to subvert the host&#x02019;s immune defences and establish a systemic infection. This begins with the germination of spores in the infected host and release of two major toxins namely lethal toxin and edema toxin. The lethal toxin consists of PA protein and an enzymatic moiety, LF, whereas edema toxin contains PA protein and the EF enzymatic moiety. Individually, these three toxins are harmless. Both LF and EF require binding to PA for expression of their respective activity. PA, which is a 83 kDa-soluble protein, serves as a central component for the other two toxins (<xref rid="toxins-17-00056-t001" ref-type="table">Table 1</xref>). LF is a Zn-dependent protease and cleaves the mitogen-activated protein kinase kinases (MAPKKs), leading to the inactivation of intracellular signalling cascades of the host [<xref rid="B52-toxins-17-00056" ref-type="bibr">52</xref>,<xref rid="B53-toxins-17-00056" ref-type="bibr">53</xref>]. This interference hampers the host&#x02019;s immune response and contributes to the bacteria&#x02019;s ability to evade immune surveillance [<xref rid="B54-toxins-17-00056" ref-type="bibr">54</xref>]. EF, an adenylate cyclase act by increasing intracellular cyclic Adenosine Monophosphate (cAMP) levels, disrupting cellular homeostasis by interfering with various cellular functions, including immune cells and contribute to the characteristic edema observed in anthrax infections [<xref rid="B55-toxins-17-00056" ref-type="bibr">55</xref>,<xref rid="B56-toxins-17-00056" ref-type="bibr">56</xref>]. PA binds to capillary morphogenesis protein-2 (CMG2) or tumor endothelial marker-8 (TEM8) by its C-Terminal with the help of metal-ion dependent adhesion site (MIDAS) coordinating the divalent ions and facilitates entry of LF and EF into host cells. After binding, the 20 kDa sequence of PA is cleaved by the furin family of cellular proteases at the sequence RKKR. After the sterically inhibiting unit of PA20 is removed, the cleaved 63 kDa PA now forms a ring shaped octamer. The oligomerization of the PA63 takes place by refolding in the FFD (315) domain. The oligomer can bind to maximum 3 molecules of LF and EF [<xref rid="B57-toxins-17-00056" ref-type="bibr">57</xref>]. PA-bound LF or EF are engulfed via receptor-mediated endocytosis. This is followed by the acidification of endosomes which facilitate the PA insertion into the endosome membrane, forming a channel through which the unfolded form of LF and EF can translocate to the cytosol via Brownian motion [<xref rid="B58-toxins-17-00056" ref-type="bibr">58</xref>,<xref rid="B59-toxins-17-00056" ref-type="bibr">59</xref>] (<xref rid="toxins-17-00056-f006" ref-type="fig">Figure 6</xref>).</p><p>Anthrolysin O (ALO), another secreted virulence factor, is a cholesterol-dependent cytolysin that targets host cell membranes. ALO binds to cholesterol, forming large pores in cell membranes, which disrupts membrane integrity and leads to cell lysis. Strains secreting ALO cross host cell layers more effectively than ALO-deficient strains, highlighting its role in virulence. ALO primarily targets immune cells, including monocytes, neutrophils and macrophages, promoting the bacterium&#x02019;s evasion of the host&#x02019;s initial immune response and facilitating systemic spread [<xref rid="B50-toxins-17-00056" ref-type="bibr">50</xref>,<xref rid="B60-toxins-17-00056" ref-type="bibr">60</xref>].</p><p>The poly-D-glutamic acid capsule of <italic toggle="yes">B. anthracis</italic> serves as a protective shield against immune attack. Weakly immunogenic, the capsule prevents opsonization, which is the immune system&#x02019;s method of marking pathogens for destruction. This allows the bacteria to evade phagocytosis and continue its proliferation within the host. The capsule&#x02019;s production is controlled by the pXO2 plasmid and is upregulated in response to elevated carbon dioxide levels, signaling the bacterium&#x02019;s transition from the environment to a host [<xref rid="B50-toxins-17-00056" ref-type="bibr">50</xref>,<xref rid="B61-toxins-17-00056" ref-type="bibr">61</xref>].</p><table-wrap position="anchor" id="toxins-17-00056-t001"><object-id pub-id-type="pii">toxins-17-00056-t001_Table 1</object-id><label>Table 1</label><caption><p>Virulence factors of <italic toggle="yes">B. anthracis</italic> and their roles in anthrax pathogenesis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virulence Factor <break/>(Encoded by)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective Antigen (PA) <break/>(pXO1 plasmid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83 kDa protein serving as a central component of anthrax toxins. <break/>Binds to receptors CMG2 and TEM8 via MIDAS (metal&#x02013;ion dependent adhesion site). <break/>Cleaved by furin proteases into PA20 (removed) and PA63 (active). <break/>Forms octameric rings, binding LF or EF.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Facilitates entry of LF and EF into host cells.<break/>Forms a channel in the endosome membrane for LF/EF translocation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-toxins-17-00056" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal Factor (LF)<break/>(pXO1 plasmid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zn-dependent protease targeting MAPKKs.<break/>Requires PA to enter host cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivates MAPK signaling, <break/>disrupting intracellular signaling. <break/>Hampers host immune response and contributes to immune evasion.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-toxins-17-00056" ref-type="bibr">52</xref>,<xref rid="B53-toxins-17-00056" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Edema Factor (EF)<break/>(pXO1 plasmid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenylate cyclase enzyme. <break/>Requires PA to enter host cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases intracellular cAMP levels. <break/>Disrupts cellular homeostasis, <break/>impairs immune cell functions and contributes to edema formation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-toxins-17-00056" ref-type="bibr">55</xref>,<xref rid="B56-toxins-17-00056" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiphagocytic Capsule<break/>(pXO2 plasmid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Composed of poly-D-glutamic acid.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents recognition and phagocytosis by immune cells, allowing <break/>bacterial survival and systemic spread.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-toxins-17-00056" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anthrolysin O<break/>(Chromosomally encoded)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol-dependent cytolysin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forms large pores in cell membranes, disrupts membrane integrity leading to cell lysis.<break/>Targets immune cells, promotes bacterium&#x02019;s evasion of the host&#x02019;s initial immune response and facilitates systemic spread</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-toxins-17-00056" ref-type="bibr">50</xref>,<xref rid="B60-toxins-17-00056" ref-type="bibr">60</xref>]</td></tr></tbody></table></table-wrap><sec id="sec4dot1-toxins-17-00056"><title>4.1. Anthrax Pathogenesis</title><p>LF is a mettaloproteinase that cleaves mitogen-activated protein kinase kinases (MEKs), which causes inactivation of the three key mitogen-activated protein kinase (MAPK) pathways. These pathways act in response to several stimuli, such as proinflammatory cytokines, heat shock and many other cellular stresses, which play critical roles in cell survival [<xref rid="B62-toxins-17-00056" ref-type="bibr">62</xref>]. Macrophages from some strains of rat and mouse, such as Fischer rats and BALBc mice, are sensitive to lethal toxin (LT), whereas a few strains, such as those from C57BL6 mice and Lewis rats, are resistant [<xref rid="B63-toxins-17-00056" ref-type="bibr">63</xref>]. It was shown that sensitivity to lethal toxin is due to polymorphisms in a single gene, <italic toggle="yes">Nlrp1</italic> in rats and <italic toggle="yes">Nlrp1b</italic> in mice [<xref rid="B64-toxins-17-00056" ref-type="bibr">64</xref>], and not due to cleavage of MEKs. These genes encode NOD-like receptor protein NLRP1, a component of NLRP1 inflammasome (multi-protein complex), which activates caspase-1. Lethal toxin can cleave NLRP1/NLRP1b from sensitive mice/rats, causing inactivation of NLRP1 inflammasome [<xref rid="B52-toxins-17-00056" ref-type="bibr">52</xref>] and leading to caspase-1-mediated death of macrophages, called pyroptosis. Later, an interesting observation was reported, that while LT sensitivity of rat is directly related to NLRP1 [<xref rid="B64-toxins-17-00056" ref-type="bibr">64</xref>], mice are killed in a manner independent of their macrophage sensitivity to the toxin. This observation suggests the role of other cell types in lethality [<xref rid="B65-toxins-17-00056" ref-type="bibr">65</xref>].</p><p>The edema factor of Edema Toxin (ET) has adenylyl cyclase activity, which increases cellular cAMP levels, causing multiple effects such as skin and liver edema, and it can induce fluid influx in the intestinal lumen, causing extensive tissue damage and death [<xref rid="B66-toxins-17-00056" ref-type="bibr">66</xref>]. cAMP has been shown to have at least two major targets, which include protein kinase A (PKA) and an exchange protein activated by cAMP. Binding of cAMP to regulatory units of PKA causes the release of a catalytic monomer which is activated by ATP, leading to phosphorylation of many substrates. Increased levels of cAMP by cholera toxins is known to cause intestinal fluid secretion by activating cystic fibrosis transmembrane conductance regulator [<xref rid="B67-toxins-17-00056" ref-type="bibr">67</xref>], and possibly this mechanism is also followed by ET-induced intestinal secretion.</p><p>In the beginning of infection, anthrax toxin complex (LT and ET) weakens the immune system, which helps in the establishment of the disease. In later stages, toxins, together with bacterial infection, cause death by targeting the liver and other vital organs of the host [<xref rid="B66-toxins-17-00056" ref-type="bibr">66</xref>].</p></sec><sec id="sec4dot2-toxins-17-00056"><title>4.2. Anthrax Toxin in Cancer Therapeutics</title><p>Cancer is a leading cause of death worldwide and was responsible for approximately 9.6 million deaths in 2018, as per a WHO report [<xref rid="B68-toxins-17-00056" ref-type="bibr">68</xref>]. Due to the growing global cancer burden [<xref rid="B69-toxins-17-00056" ref-type="bibr">69</xref>], there is an urgent need to develop safe, effective and accessible therapies to treat this slow poison.</p><p>One of the primary front-line therapies for cancer is the surgical removal of the tumor from a patient&#x02019;s body. Another mainstay treatment is radiation therapy, in which ionising radiation is used to irradiate the cancerous region that leads to tumor death due to DNA damage. The mechanism of this therapy is generic and non-selective; thus normal, surrounding tissue is also affected that can lead to acute and/or late toxicity [<xref rid="B70-toxins-17-00056" ref-type="bibr">70</xref>]. Chemotherapy, another common method of treatment, works on the principle of utilising toxic compounds and drugs to eliminate cancerous cells [<xref rid="B71-toxins-17-00056" ref-type="bibr">71</xref>,<xref rid="B72-toxins-17-00056" ref-type="bibr">72</xref>]. Over the years, various natural medicinal compounds and anti-cancer drugs have been devised to target tumors more quickly and effectively while minimizing damage to other surrounding healthy cells [<xref rid="B72-toxins-17-00056" ref-type="bibr">72</xref>,<xref rid="B73-toxins-17-00056" ref-type="bibr">73</xref>,<xref rid="B74-toxins-17-00056" ref-type="bibr">74</xref>,<xref rid="B75-toxins-17-00056" ref-type="bibr">75</xref>]. Different types of chemotherapy affect target cells in various ways. Certain treatments may directly modify the quality of cellular proteins, disrupting their functionality and interfering with essential major cellular physiological processes while other treatments target crucial cellular enzymes or may modify cellular metabolism. Chemotherapy also interferes with some critical cellular processes, such as, drug resistance, programmed cell death/apoptosis, DNA damage and replication or immune reactions [<xref rid="B76-toxins-17-00056" ref-type="bibr">76</xref>,<xref rid="B77-toxins-17-00056" ref-type="bibr">77</xref>,<xref rid="B78-toxins-17-00056" ref-type="bibr">78</xref>,<xref rid="B79-toxins-17-00056" ref-type="bibr">79</xref>,<xref rid="B80-toxins-17-00056" ref-type="bibr">80</xref>]. Resistance to different chemotherapeutic agents may also develop [<xref rid="B71-toxins-17-00056" ref-type="bibr">71</xref>].</p><p>The conventional therapies to treat cancer as discussed above have limitations and side-effects beyond imagination. Thus, in the pursuit of scrupulous and precise methods, researchers explored the molecular-targeted therapies which reduced poor drug accumulation in the tumor cell and increased efficiency [<xref rid="B81-toxins-17-00056" ref-type="bibr">81</xref>]. Over the past decades, bacteria-mediated cancer therapy has emerged to be one of the novel therapies to overcome the limitations of the conventional therapies [<xref rid="B49-toxins-17-00056" ref-type="bibr">49</xref>]. To date, three recombinant immunotoxins have received marketing approval for the treatment of hematological cancers namely moxetumomab, pasudotox (anti-CD22) and Denileukin diftitox (Ontak<sup>&#x000ae;</sup>) [<xref rid="B82-toxins-17-00056" ref-type="bibr">82</xref>]. Bacteria are known to have anti-tumour property by triggering the immune response through various mechanisms [<xref rid="B82-toxins-17-00056" ref-type="bibr">82</xref>]. Bacterial toxins or AB toxins have been efficiently used to transport toxic subunits into the cell [<xref rid="B81-toxins-17-00056" ref-type="bibr">81</xref>]. The AB toxins are classified into different groups based on their structure (<xref rid="toxins-17-00056-t002" ref-type="table">Table 2</xref>) [<xref rid="B81-toxins-17-00056" ref-type="bibr">81</xref>].</p><p>Both Tumor endothelial marker-8 (TEM8 or ANTRX1) and capillary morphogenesis gene-2 (CMG2 or ANTXR2) play a role in tumor angiogenesis, making them potential targets for cancer therapy [<xref rid="B83-toxins-17-00056" ref-type="bibr">83</xref>,<xref rid="B84-toxins-17-00056" ref-type="bibr">84</xref>,<xref rid="B85-toxins-17-00056" ref-type="bibr">85</xref>,<xref rid="B86-toxins-17-00056" ref-type="bibr">86</xref>,<xref rid="B87-toxins-17-00056" ref-type="bibr">87</xref>]. This possibility is aided by the presence of unique features in the anthrax toxin proteins that allow their engineering for conversion into specific anticancer agents [<xref rid="B88-toxins-17-00056" ref-type="bibr">88</xref>]. For this purpose, their specificity towards tumor cells must be increased. One way of achieving this was based on the prerequisite of proteolytic activation of PA on the cell surface along with the understanding that tumor cells produces higher level of urokinase-type plasminogen activator (uPA) and cell-surface matrix metalloproteinases (MMPs) (<xref rid="toxins-17-00056-f007" ref-type="fig">Figure 7</xref>). Hence, the RKKR sequence, which is the furin target sequence on PA, was replaced with sequences recognized by MMP or uPA, creating targeted anti-tumor agents. [<xref rid="B89-toxins-17-00056" ref-type="bibr">89</xref>,<xref rid="B90-toxins-17-00056" ref-type="bibr">90</xref>,<xref rid="B91-toxins-17-00056" ref-type="bibr">91</xref>,<xref rid="B92-toxins-17-00056" ref-type="bibr">92</xref>]. The specificity for tumors was further increased by designing intermolecular complementing PA variants with the presence of both MMPs and uPA for activation [<xref rid="B92-toxins-17-00056" ref-type="bibr">92</xref>,<xref rid="B93-toxins-17-00056" ref-type="bibr">93</xref>,<xref rid="B94-toxins-17-00056" ref-type="bibr">94</xref>]. This method, based on the observation that tumor and stromal cells in cancer often overexpress MMPs and uPA [<xref rid="B95-toxins-17-00056" ref-type="bibr">95</xref>,<xref rid="B96-toxins-17-00056" ref-type="bibr">96</xref>,<xref rid="B97-toxins-17-00056" ref-type="bibr">97</xref>], ensures that these PA variants are selectively activated in solid tumours. This selective activation facilitates the targeted delivery of effector proteins, e.g., LF or recombinant LF fusion proteins, into the cytoplasm of tumour target cells where they can produce various cytotoxic effects.</p><p>The intrinsic activity of native LF involves inactivation of mitogen- activated protein kinase kinases (MEKs), which shuts down the RAS-RAF-MEK-ERK (Rat Sarcoma&#x02014;Rapidly Accelerated Fibrosarcoma&#x02014;Mitogen-Activated Protein Kinase Kinase&#x02014;Extracellular Signal-Regulated Kinase) signalling pathway [<xref rid="B98-toxins-17-00056" ref-type="bibr">98</xref>,<xref rid="B99-toxins-17-00056" ref-type="bibr">99</xref>]. Interestingly, oncogenic mutations in this pathway are commonly observed in human cancers [<xref rid="B100-toxins-17-00056" ref-type="bibr">100</xref>]. Therefore, the inherent activity of LF against this pathway highlights another distinct characteristic of the engineered anthrax lethal toxins that enhances their efficacy in tumor targeting. These attributes have positioned these engineered LF toxins as a promising new category of powerful agents for targeted cancer treatment.</p><p>The toxin is re-engineered and modified such that it is specific and toxic for cancer cells. In one such study, the anthrax toxin was fused with zymogen activating prodrug and to make it specific for ovarian cancer cells, the PA was modified such that now it could be activated my membrane-anchored serine proteases (MASPs) instead of the classical activation by furin cleavage at RKKR because the MASPs are overexpressed in the ovarian cancer. Upon activation the LF factor is translocated to cytosol where it inactivates MAP kinase pathways thus modulating gene expression [<xref rid="B101-toxins-17-00056" ref-type="bibr">101</xref>]. Breast cancer is one of the most diagnosed cancers in women. These are heterogeneous tumours, which exhibit over-expression of the MAPK/ERK pathway, which is involved in the regulation of cell proliferation, differentiation and death. LF upon translocation to cytosol inhibits MAPK/ERK pathway due to zinc- activated metalloprotease and thus inhibits the invasion and migratory capacities of breast cancer cells. ERK inhibits cell adhesion in order to promote cell migration by inactivating RhoA and LeTx treatment increases this activity in addition to the Cdc42 [<xref rid="B102-toxins-17-00056" ref-type="bibr">102</xref>].</p><p>The PA domain can be mutated to target HER2 receptor, which is commonly found overexpressed in the breast, gastric and ovarian carcinomas [<xref rid="B103-toxins-17-00056" ref-type="bibr">103</xref>,<xref rid="B104-toxins-17-00056" ref-type="bibr">104</xref>,<xref rid="B105-toxins-17-00056" ref-type="bibr">105</xref>,<xref rid="B106-toxins-17-00056" ref-type="bibr">106</xref>,<xref rid="B107-toxins-17-00056" ref-type="bibr">107</xref>]. They fused a high-affinity Affibody specific for the HER2 receptor namely ZHER2:342 to the C-terminus of the PA domain of the anthrax toxin. This antibody was derived from the z-domain of the <italic toggle="yes">Staphylococcus aureus</italic> protein A. These fusion proteins exhibited a cytocidal effect on the HER2 positive tumour cells [<xref rid="B103-toxins-17-00056" ref-type="bibr">103</xref>,<xref rid="B108-toxins-17-00056" ref-type="bibr">108</xref>].</p></sec></sec><sec id="sec5-toxins-17-00056"><title>5. Role of Kinases and Phosphatases in Sporulation, Germination and Virulence of <italic toggle="yes">Bacillus anthracis</italic></title><p>Protein phosphorylation plays a pivotal role in regulating bacterial pathogenesis, a concept that traces its origins to the groundbreaking discovery by Edmond Fischer and Edwin Krebs in 1955 [<xref rid="B109-toxins-17-00056" ref-type="bibr">109</xref>]. This dynamic regulatory mechanism involves the addition and removal of phosphate groups on specific amino acids, a process catalyzed by protein kinases and phosphatases, which alter the activity and function of target proteins [<xref rid="B3-toxins-17-00056" ref-type="bibr">3</xref>,<xref rid="B110-toxins-17-00056" ref-type="bibr">110</xref>]. In <italic toggle="yes">B. anthracis</italic>, the role of protein phosphorylation is especially significant orchestrating essential stages of its life cycle, including toxin production and virulence [<xref rid="B4-toxins-17-00056" ref-type="bibr">4</xref>]. Central to this regulation is AtxA, the master virulence regulator that controls the expression of anthrax toxin and capsule biosynthesis genes [<xref rid="B4-toxins-17-00056" ref-type="bibr">4</xref>,<xref rid="B111-toxins-17-00056" ref-type="bibr">111</xref>,<xref rid="B112-toxins-17-00056" ref-type="bibr">112</xref>,<xref rid="B113-toxins-17-00056" ref-type="bibr">113</xref>]. AtxA contains two phosphotransferase system regulation domains (PRDs) and an EIIB-like domain, which can be phosphorylated at specific histidine residues. Phosphorylation at His199 in PRD1 is essential for AtxA&#x02019;s DNA-binding ability, while dephosphorylation at His379 in PRD2 and the EIIB domain promotes AtxA dimerization, the active form required for its regulatory function [<xref rid="B113-toxins-17-00056" ref-type="bibr">113</xref>,<xref rid="B114-toxins-17-00056" ref-type="bibr">114</xref>,<xref rid="B115-toxins-17-00056" ref-type="bibr">115</xref>]. This regulation is mediated by the phosphoenolpyruvate phosphotransferase system (PEP-PTS), a multicomponent system that serves as a key link between carbon source availability and the regulation of virulence factors [<xref rid="B116-toxins-17-00056" ref-type="bibr">116</xref>,<xref rid="B117-toxins-17-00056" ref-type="bibr">117</xref>]. In <italic toggle="yes">B. anthracis</italic>, deletion of PTS proteins (HPr and Enzyme I) results in decreased <italic toggle="yes">atxA</italic> transcription and anthrax toxin production indicating the crucial role of PTS in anthrax virulence [<xref rid="B118-toxins-17-00056" ref-type="bibr">118</xref>]. By influencing the expression of genes involved in toxin production, this system helps <italic toggle="yes">B. anthracis</italic> adjust their pathogenic potential according to environmental nutrient conditions. AtxA&#x02019;s role extends beyond toxin production; it also influences the bacterium&#x02019;s decision to sporulate or maintain a virulent state. High levels of AtxA are linked to increased toxin expression and reduced sporulation, a strategic balance that allows <italic toggle="yes">B. anthracis</italic> to either persist in the environment as spores or actively infect and replicate within a host [<xref rid="B111-toxins-17-00056" ref-type="bibr">111</xref>]. This dual role of AtxA highlights the sophisticated regulatory mechanisms driven by phosphorylation that enable <italic toggle="yes">B. anthracis</italic> to switch between survival modes based on nutrient availability and other host-derived signals. In addition to histidine phosphorylation, serine/threonine kinases and phosphatases also play crucial roles in the virulence pathways of <italic toggle="yes">B. anthracis</italic>. Strains lacking the ser/thr kinase (PrkC) and phosphatase (PrpC) pair exhibit attenuated virulence and impaired bacterial survival in macrophages in animal models of anthrax [<xref rid="B119-toxins-17-00056" ref-type="bibr">119</xref>]. The serine/threonine phosphatase PrpN is also vital for regulating anthrax toxin synthesis. Mutant strains deficient in PrpN show reduced expression of anthrax toxins (PA and LF) and the toxin activator protein AtxA [<xref rid="B16-toxins-17-00056" ref-type="bibr">16</xref>]. This defect is linked to the phosphorylation of CodY at Ser215 in its DNA-binding domain, which prevents its binding to the <italic toggle="yes">atxA</italic> promoter, a critical step in activating anthrax toxin gene expression [<xref rid="B16-toxins-17-00056" ref-type="bibr">16</xref>,<xref rid="B120-toxins-17-00056" ref-type="bibr">120</xref>,<xref rid="B121-toxins-17-00056" ref-type="bibr">121</xref>]. </p><p>In terms of phosphorylation mediated signaling pathways in bacteria, the most well-studied signaling mechanisms is a two-component systems (TCSs) [<xref rid="B122-toxins-17-00056" ref-type="bibr">122</xref>,<xref rid="B123-toxins-17-00056" ref-type="bibr">123</xref>,<xref rid="B124-toxins-17-00056" ref-type="bibr">124</xref>], with one component is a sensor histidine kinase (HK), which is a membrane bound and the other is a response regulator (RR), which is a cytoplasmic. On stimulation, the HK component autophosphorylates on a conserved histidine residue and the phosphate group is then transferred to the response regulator at its specific aspartic acid residue, thereby activating the RR. This RR then binds to the target DNA and alters the gene expression [<xref rid="B125-toxins-17-00056" ref-type="bibr">125</xref>,<xref rid="B126-toxins-17-00056" ref-type="bibr">126</xref>,<xref rid="B127-toxins-17-00056" ref-type="bibr">127</xref>]. </p><p>In <italic toggle="yes">B. anthracis</italic>, TCSs play a vital role in modulating virulence factors, including the lethal and edema toxins. For instance, the BrrA-BrrB TCS regulates the expression of anthrax toxin genes during infection. Disruption of either component in this system significantly reduces the bacterium&#x02019;s ability to produce toxins, resulting in attenuated virulence [<xref rid="B128-toxins-17-00056" ref-type="bibr">128</xref>]. Moreover, TCSs, such as the HssRS and HitRS systems, allow <italic toggle="yes">B. anthracis</italic> to sense and respond to heme toxicity and cell envelope stress, respectively [<xref rid="B127-toxins-17-00056" ref-type="bibr">127</xref>,<xref rid="B128-toxins-17-00056" ref-type="bibr">128</xref>,<xref rid="B129-toxins-17-00056" ref-type="bibr">129</xref>] <italic toggle="yes">B. anthracis</italic> uses the HssRS two-component system to sense and respond to heme toxicity during infection. In the host, HssRS regulates the expression of the heme transporter, HrtAB (heme detoxification system) and allows <italic toggle="yes">B. anthracis</italic> to proliferate to high levels in vertebrate tissues during anthrax pathogenesis by acquiring iron from host heme while avoiding heme toxicity [<xref rid="B129-toxins-17-00056" ref-type="bibr">129</xref>]. Interestingly, HitRS triggers the expression of the same gene pool as the heme sensing HssRS TCS [<xref rid="B127-toxins-17-00056" ref-type="bibr">127</xref>,<xref rid="B130-toxins-17-00056" ref-type="bibr">130</xref>].</p><p>Phosphorelays, which are more elaborate versions of two-component systems, enable more complex regulatory control in <italic toggle="yes">B. anthracis</italic>. These systems involve multiple phosphotransfer steps, allowing for fine-tuned regulation of sporulation and other cellular processes. Spo0A, the master regulator of sporulation is activated by a complex phosphorelay system involving multiple histidine sensor kinases (HKs) and response regulators (RRs) [<xref rid="B131-toxins-17-00056" ref-type="bibr">131</xref>,<xref rid="B132-toxins-17-00056" ref-type="bibr">132</xref>]. The main proteins involved are Spo0F (response regulator), Spo0B (phosphotransferase) and Spo0A (master transcription factor) [<xref rid="B13-toxins-17-00056" ref-type="bibr">13</xref>,<xref rid="B132-toxins-17-00056" ref-type="bibr">132</xref>,<xref rid="B133-toxins-17-00056" ref-type="bibr">133</xref>]. The goal of the phosphorelay is to activate Spo0A through phosphorylation (Spo0A~P) that functions as a transcription factor and regulates genes critical for sporulation and virulence. This activation is reversed by the Spo0E and Rap phosphatase, which dephosphorylates Spo0A and Spo0F RR, providing an additional layer of control [<xref rid="B13-toxins-17-00056" ref-type="bibr">13</xref>,<xref rid="B134-toxins-17-00056" ref-type="bibr">134</xref>]. Additionally, two other TCSs, BAS1213&#x02013;1214 and BAS0540&#x02013;0541, have been identified in sporulation modulation. Upregulation of either BAS1213 or BAS0540 RRs significantly reduces sporulation efficiency [<xref rid="B135-toxins-17-00056" ref-type="bibr">135</xref>,<xref rid="B136-toxins-17-00056" ref-type="bibr">136</xref>]. Serine/threonine phosphorylation also impacts sporulation, as strains deficient in the serine/threonine phosphatase PrpN show marked sporulation defects [<xref rid="B16-toxins-17-00056" ref-type="bibr">16</xref>]. </p><p>Beyond its role in toxin production and sporulation, protein phosphorylation in <italic toggle="yes">B. anthracis</italic> regulates a range of virulence-associated traits, including spore germination, chaining morphology and biofilm formation. The serine/threonine kinase PrkC is particularly significant in regulating these lifecycle transitions. PrkC phosphorylates key enzymes such as enolase and GroEL, thereby modulating spore germination and biofilm development [<xref rid="B137-toxins-17-00056" ref-type="bibr">137</xref>,<xref rid="B138-toxins-17-00056" ref-type="bibr">138</xref>]. Enolase overexpression during sporulation disrupts germination and PrkC-mediated phosphorylation of enolase reduces its catalytic activity while also modulating its expression and localization. This regulatory phosphorylation by PrkC, therefore, plays a crucial role in controlling the overall spore germination process [<xref rid="B138-toxins-17-00056" ref-type="bibr">138</xref>]. The PrkC-PrpC kinase-phosphatase pair also reversibly controls the phosphorylation of GroEL, an essential chaperone involved in biofilm formation [<xref rid="B139-toxins-17-00056" ref-type="bibr">139</xref>]. Additionally, PrkC also regulates chain formation, a virulence factor that aids in immune evasion, as strains deficient in PrkC show severe defects in chain formation [<xref rid="B140-toxins-17-00056" ref-type="bibr">140</xref>]. </p><p>In conclusion, protein phosphorylation serves as a central regulatory mechanism that allows <italic toggle="yes">B. anthracis</italic> to fine-tune its response to environmental signals, optimize energy usage and coordinate virulence factor expression. A deeper understanding of these phosphorylation driven pathways will provide valuable insights into the molecular strategies employed by <italic toggle="yes">B. anthracis</italic> to establish infection and evade host defences. This knowledge opens new opportunities for targeted therapeutic interventions. Drugs designed to modulate specific phosphorylation events could effectively disrupt key processes such as virulence factor expression, sporulation and biofilm formation; thereby weakening the pathogen&#x02019;s ability to adapt and persist within the host. Such an approach offers the potential to attenuate infection and reduce the severity of anthrax cases. As research in this field advances, bacterial kinases and their associated phosphorylation events are emerging as attractive targets for drug developments [<xref rid="B141-toxins-17-00056" ref-type="bibr">141</xref>,<xref rid="B142-toxins-17-00056" ref-type="bibr">142</xref>]. Moreover the broader implications of targeting phosphorylation in bacterial pathogens extend beyond anthrax. The conserved nature of kinase-regulatory pathways across many bacterial species suggest that insights gained from studying <italic toggle="yes">B. anthracis</italic> could inform development of therapies for other bacterial infections. The intricate interplay between phosphorylation-driven processes and virulence underscores the importance of continued research into these regulatory mechanisms.</p></sec><sec id="sec6-toxins-17-00056"><title>6. Prevention and Treatment of Anthrax</title><p>Vegetative forms of <italic toggle="yes">B</italic>. <italic toggle="yes">anthracis</italic> are susceptible to most antibiotics with penicillin G and amoxicillin or ciprofloxacin [<xref rid="B42-toxins-17-00056" ref-type="bibr">42</xref>]. In inhalation anthrax, mechanical ventilation can be given to patients to prevent respiratory failure. For treatment of gastrointestinal anthrax, combination of penicillin G with streptomycin or aminoglycosides in adequate dose intravenously could be effective. Sometimes, surgical treatment to treat gastrointestinal anthrax may be required. Although rare, anthrax meningoencephalitis requires antibiotic treatment for a longer time. It has been reported that some strains of <italic toggle="yes">B. anthracis</italic> are naturally resistant to penicillin and in such cases appropriate antibiotics need to be administered to the patients. Often anthrax infections are diagnosed late and by this time its toxin levels become lethal. While antibiotics can kill bacteria, it can neutralize anthrax toxin. Two monoclonal antibodies, namely Raxibacumab [<xref rid="B143-toxins-17-00056" ref-type="bibr">143</xref>] and obiltoxaximab [<xref rid="B144-toxins-17-00056" ref-type="bibr">144</xref>], which targets protective antigens have been developed and approved by Food and Drug Administration USA (US FDA) for treatment of patients.</p><p>Vaccines have been one of the most effective public health tools, drastically reducing the prevalence of many infectious diseases. In the case of anthrax, several types of vaccines have been developed to target its unique mechanisms of infection [<xref rid="B145-toxins-17-00056" ref-type="bibr">145</xref>]. Whole-cell vaccines use live, attenuated (weakened) forms of <italic toggle="yes">B. anthracis</italic>, allowing the immune system to build a strong defense. However, they require multiple doses and sometimes cause side effects. Protein-based vaccines, on the other hand, focus on specific anthrax proteins, like the protective antigen (PA), which is crucial for toxin entry into host cells. PA-based vaccines are safer and stimulate immunity against anthrax toxins without using live bacteria [<xref rid="B146-toxins-17-00056" ref-type="bibr">146</xref>,<xref rid="B147-toxins-17-00056" ref-type="bibr">147</xref>]. Another category of vaccines are capsule vaccines that utilize the capsule composed of poly-&#x003b3;-D-glutamic acid to target the capsule that surrounds <italic toggle="yes">B. anthracis</italic>. Toxin vaccines, on the other hand, use anthrax toxins such as protective antigen (PA), lethal factor (LF) and edema factor (EF) in combination to broaden immunity and neutralize the toxins effectively.</p><p>Historically, there are three major vaccines in use for anthrax, namely, BioThrax (AVA or Anthrax vaccine adsorbed), Anthrax vaccine precipitated (AVP) and Live anthrax vaccine (LAV). BioThrax and AVP are cell-free protein-based vaccines, whereas LAV is a spore-based vaccine (<xref rid="toxins-17-00056-t003" ref-type="table">Table 3</xref>). Recently, the US FDA has approved the use of another anthrax vaccine named CYFENDUS&#x02122; (AV7909), which is similar to BioThrax but contains an additional adjuvant, CPG 7909, which enhances its immunogenicity.</p><p>BioThrax (AVA), developed in the United States, is derived from a cell-free filtrate of the <italic toggle="yes">B. anthracis</italic> strain V770-NP1-R (BioThrax | FDA) [<xref rid="B148-toxins-17-00056" ref-type="bibr">148</xref>,<xref rid="B149-toxins-17-00056" ref-type="bibr">149</xref>]. It contains the PA protein, which stimulates immunity against anthrax toxins. BioThrax is administered intramuscularly in a multi-dose series followed by booster doses to maintain immunity. Anthrax Vaccine Precipitated (AVP), used in the UK is a cell-free formulation made from the Sterne 34F2 strain of <italic toggle="yes">B. anthracis</italic> [<xref rid="B146-toxins-17-00056" ref-type="bibr">146</xref>,<xref rid="B150-toxins-17-00056" ref-type="bibr">150</xref>]. It includes PA, LF and small amounts of EF protein, generating a broader immune response than PA alone. AVP also requires multiple doses with boosters for long-term protection. Live Anthrax Vaccine (LAV) developed in Russia, was composed of non-encapsulated live spores from two different strains of <italic toggle="yes">B. anthracis</italic> (STI-1 and NO 3) [<xref rid="B151-toxins-17-00056" ref-type="bibr">151</xref>,<xref rid="B152-toxins-17-00056" ref-type="bibr">152</xref>]. In the next version of this vaccine, LAV STI-1 only STI-1 strain was used. LAV can be administered cutaneously or subcutaneously and requires multiple annual doses to sustain immunity.</p><p>Subsequently, various studies have been conducted to increase the immunogenicity of the above vaccines by utilising different adjuvants [<xref rid="B153-toxins-17-00056" ref-type="bibr">153</xref>]. For example, AV7909 is AVA adjuvanted with CPG 7909, a immunostimulatory oligodeoxynucleotide [<xref rid="B154-toxins-17-00056" ref-type="bibr">154</xref>,<xref rid="B155-toxins-17-00056" ref-type="bibr">155</xref>]. Similarly, STI-1+ PA is LAV adjuvanted with PA adsorbed on aluminium hydroxide [<xref rid="B152-toxins-17-00056" ref-type="bibr">152</xref>].</p><table-wrap position="anchor" id="toxins-17-00056-t003"><object-id pub-id-type="pii">toxins-17-00056-t003_Table 3</object-id><label>Table 3</label><caption><p>Major anthrax vaccines in use and their properties.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Details <break/>(References)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioThrax<sup>&#x000ae;</sup> (AVA or Anthrax vaccine adsorbed)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Derived from cell-free extracts of an avirulent strain of <break/><italic toggle="yes">B. anthracis</italic> (V770-NP1-R strain) with alum as the adjuvant. <break/>Immunogen- PA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-exposure prophylaxis&#x02014;intramuscular injection.<break/>Post-exposure prophylaxis&#x02014;subcutaneously.<break/>Pre-exposure prophylaxis&#x02014;Primary doses at 0, 1 and 6 months. After completion of primary series, booster vaccinations at 6 and 12 months followed by annual booster thereafter.<break/>Post-exposure prophylaxis&#x02014;Doses at 0, 2 and 4 weeks. <break/>[<xref rid="B148-toxins-17-00056" ref-type="bibr">148</xref>,<xref rid="B149-toxins-17-00056" ref-type="bibr">149</xref>,<xref rid="B156-toxins-17-00056" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYFENDUS&#x02122;, also known as AV7909</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Same as BioThrax with an additional adjuvant, CPG 7909 in addition to alum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administered by intramuscular injections and only during post-exposure prophylaxis.<break/>Two doses at Week 0 and Week 2. <break/>[<xref rid="B157-toxins-17-00056" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AVP or Anthrax vaccine precipitated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Derived from cell-free extract of the vaccine strain <italic toggle="yes">B. anthracis</italic> Sterne 34F2 strain, precipitated with alum.<break/>Immunogen- Composed mostly of PA and LF. Also, traces of EF present.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular injection.<break/>Doses at 0, 3, 6 and 32 weeks.<break/>Boosters annually thereafter <break/>[<xref rid="B146-toxins-17-00056" ref-type="bibr">146</xref>,<xref rid="B150-toxins-17-00056" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live anthrax vaccine (LAV).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live-attenuated anthrax vaccine<break/>Consists of dry spores of nonencapsulated <italic toggle="yes">B. anthracis</italic> variants (STI-1 and NO 3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous and subcutaneous administration.<break/>Annual doses for three years, with boosts every two years thereafter. <break/>[<xref rid="B151-toxins-17-00056" ref-type="bibr">151</xref>,<xref rid="B152-toxins-17-00056" ref-type="bibr">152</xref>]</td></tr></tbody></table></table-wrap><p>Additionally, recombinant vaccines and DNA vaccines have also been developed. For instance, plasmid DNA vaccines coding for PA and LF [<xref rid="B158-toxins-17-00056" ref-type="bibr">158</xref>] and adenovirus packaged vaccine [<xref rid="B159-toxins-17-00056" ref-type="bibr">159</xref>,<xref rid="B160-toxins-17-00056" ref-type="bibr">160</xref>,<xref rid="B161-toxins-17-00056" ref-type="bibr">161</xref>]. A live attenuated vaccine with mutations in genes that make the bacillus acapsular has also been developed [<xref rid="B162-toxins-17-00056" ref-type="bibr">162</xref>]. Also, a whole-cell vaccine consisting of killed but metabolically active bacteria is being used as a vaccine [<xref rid="B163-toxins-17-00056" ref-type="bibr">163</xref>].</p><p>Anthrax infections in humans and animals are often diagnosed late and can be fatal [<xref rid="B164-toxins-17-00056" ref-type="bibr">164</xref>,<xref rid="B165-toxins-17-00056" ref-type="bibr">165</xref>] However, early diagnosis allows effective treatment with antibiotics, immunotherapy and toxin inhibitors. The primary treatment involves antibiotics such as ciprofloxacin, levofloxacin, penicillin and doxycycline, often combined with antitoxins [<xref rid="B166-toxins-17-00056" ref-type="bibr">166</xref>]. Ciprofloxacin is a commonly used antibiotic to treat anthrax globally [<xref rid="B167-toxins-17-00056" ref-type="bibr">167</xref>].</p><p>Extensive research has been conducted to develop specific inhibitors targeting virulence factors like LF, EF, PA and capsule. Efforts also focus on creating inhibitors for anthrax toxin receptors and furin endoproteases necessary for toxin activation. Recently, the antimalarial drug amodiaquine (AQ) has been suggested as adjunctive therapy for anthrax, as it inhibits anthrax toxin endocytosis in the host [<xref rid="B168-toxins-17-00056" ref-type="bibr">168</xref>]. The FDA currently recommends three antitoxins for systemic anthrax cases: Raxibacumab, ANTHRASIL (Anthrax Immunoglobulin Intravenous&#x02014;AIGIV) and Obiltoxaximab (Anthim/ETI-204) [<xref rid="B169-toxins-17-00056" ref-type="bibr">169</xref>,<xref rid="B170-toxins-17-00056" ref-type="bibr">170</xref>,<xref rid="B171-toxins-17-00056" ref-type="bibr">171</xref>]. These antitoxins block the binding of PA to cell surface receptors, preventing the translocation of LF and EF.</p><p>Research into small-molecule inhibitors for <italic toggle="yes">B. anthracis</italic> virulence factors, especially lethal factors, has progressed significantly. Hydroxamate-based drugs, benzylamine-based drugs and auranofin have shown efficacy against LF activity in vivo [<xref rid="B172-toxins-17-00056" ref-type="bibr">172</xref>,<xref rid="B173-toxins-17-00056" ref-type="bibr">173</xref>,<xref rid="B174-toxins-17-00056" ref-type="bibr">174</xref>]. Combining ciprofloxacin with potent LF inhibitors offers promising future treatment options for anthrax.</p><p>Despite progress, current anthrax treatments have limitations, such as incomplete neutralization, residual toxicity, short-term protection and ineffectiveness against meningitis due to the inability to cross the blood-brain barrier. Thus, new vaccines and drugs are needed to address these issues and enhance anthrax prophylaxis strategies.</p></sec><sec sec-type="conclusions" id="sec7-toxins-17-00056"><title>7. Conclusions and Future Direction</title><p>Anthrax, caused by <italic toggle="yes">Bacillus anthracis</italic>, presents a unique challenge in diagnosis and treatment due to its initial flu-like symptoms. This similarity to common illnesses often leads to delayed diagnosis, allowing the infection to progress to potentially fatal levels. As the disease progresses undetected, toxin levels in the body can reach dangerous thresholds, significantly increasing the risk of mortality. In cases of advanced infection, a multi-faceted approach combining antibiotics with toxin-neutralizing agents has shown promise, provided they don&#x02019;t cause adverse reactions Over the past two decades several small molecules like toxin inhibitors and antibiotics, reagents and antibodies have been developed that can help in the treatment of anthrax. A comparative efficacy study of these therapeutic agents is crucial for improving our readiness to tackle anthrax outbreaks. Vaccination remains another important aspect of anthrax prevention. Currently, the standard vaccine, consisting of culture supernatant proteins adsorbed on alum, is primarily administered to occupationally exposed individuals (such as farmers, zoo employees and wool and hide handlers) and military personnel. However, this vaccine is based on older technology and may benefit from modern technology. The rarity of anthrax in the general population presents a challenge for vaccine and treatment development, as pharmaceutical companies have little financial incentive to invest in these areas. Nevertheless, given the potential for drug resistance, it would be prudent to develop effective vaccines for all infectious diseases, including anthrax, before a crisis emerges. A surge in funding during the early 21st century significantly advanced our understanding of anthrax pathogenesis and its lethal mechanisms. However, global funding for anthrax research has since declined, hampering the testing of potential protective molecules and the development of recombinant vaccines. Recent studies demonstrating the protective properties of the anthrax capsule are promising. A recombinant vaccine incorporating various virulence factors, including the capsule, could prove valuable for at-risk populations and future preparedness efforts. This approach could lead to more effective and broadly applicable vaccines, enhancing our ability to combat potential anthrax threats.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Ayush Sachan and Swapnil Gupta (Shivaji College, University of Delhi), for rendering their help in making figures of the manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Y.S., U.D. and R.B. conceptualized, supervised and provided the critical inputs throughout the preparation of the manuscript. R.B. was involved in data curation, compilation, draft preparation and proper referencing. U.D. critically analysed and edited the manuscript. N.S. was involved in literature review, draft preparation, preparation of figures and referencing. A.G. has written significant portion and provided important suggestions. P.J., C.L. and S.S. contributed towards writing a few sections of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there is no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-toxins-17-00056"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baweja</surname><given-names>R.B.</given-names></name>
<name><surname>Zaman</surname><given-names>M.S.</given-names></name>
<name><surname>Mattoo</surname><given-names>A.R.</given-names></name>
<name><surname>Sharma</surname><given-names>K.</given-names></name>
<name><surname>Tripathi</surname><given-names>V.</given-names></name>
<name><surname>Aggarwal</surname><given-names>A.</given-names></name>
<name><surname>Dubey</surname><given-names>G.P.</given-names></name>
<name><surname>Kurupati</surname><given-names>R.K.</given-names></name>
<name><surname>Ganguli</surname><given-names>M.</given-names></name>
<name><surname>Chaudhury</surname><given-names>N.K.</given-names></name>
<etal/>
</person-group><article-title>Properties of <italic toggle="yes">Bacillus anthracis</italic> spores prepared under various environmental conditions</article-title><source>Arch. Microbiol.</source><year>2008</year><volume>189</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00203-007-0295-9</pub-id><pub-id pub-id-type="pmid">17713759</pub-id>
</element-citation></ref><ref id="B2-toxins-17-00056"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Spores of <italic toggle="yes">Bacillus subtilis</italic>: Their resistance to and killing by radiation, heat and chemicals</article-title><source>J. Appl. Microbiol.</source><year>2006</year><volume>101</volume><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2005.02736.x</pub-id><pub-id pub-id-type="pmid">16907802</pub-id>
</element-citation></ref><ref id="B3-toxins-17-00056"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Humphrey</surname><given-names>S.J.</given-names></name>
<name><surname>James</surname><given-names>D.E.</given-names></name>
<name><surname>Mann</surname><given-names>M.</given-names></name>
</person-group><article-title>Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation</article-title><source>Trends Endocrinol. Metab.</source><year>2015</year><volume>26</volume><fpage>676</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.09.013</pub-id><pub-id pub-id-type="pmid">26498855</pub-id>
</element-citation></ref><ref id="B4-toxins-17-00056"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gangwal</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Sangwan</surname><given-names>N.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Dhawan</surname><given-names>U.</given-names></name>
<name><surname>Sajid</surname><given-names>A.</given-names></name>
<name><surname>Arora</surname><given-names>G.</given-names></name>
<name><surname>Singh</surname><given-names>Y.</given-names></name>
</person-group><article-title>Giving a signal: How protein phosphorylation helps <italic toggle="yes">Bacillus navigate</italic> through different life stages</article-title><source>FEMS Microbiol. Rev.</source><year>2023</year><volume>47</volume><elocation-id>fuad044</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuad044</pub-id><pub-id pub-id-type="pmid">37533212</pub-id>
</element-citation></ref><ref id="B5-toxins-17-00056"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bower</surname><given-names>W.A.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Person</surname><given-names>M.K.</given-names></name>
<name><surname>Parker</surname><given-names>C.M.</given-names></name>
<name><surname>Kennedy</surname><given-names>J.L.</given-names></name>
<name><surname>Sue</surname><given-names>D.</given-names></name>
<name><surname>Hesse</surname><given-names>E.M.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Bradley</surname><given-names>J.</given-names></name>
<name><surname>Bulitta</surname><given-names>J.B.</given-names></name>
<etal/>
</person-group><article-title>CDC Guidelines for the Prevention and Treatment of Anthrax, 2023</article-title><source>MMWR Recomm. Rep.</source><year>2023</year><volume>72</volume><fpage>1</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr7206a1</pub-id><pub-id pub-id-type="pmid">37963097</pub-id>
</element-citation></ref><ref id="B6-toxins-17-00056"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Turnbull</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Introduction: Anthrax history, disease and ecology</article-title><source>Current Topics in Microbiology and Immunology</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2002</year><volume>Volume 271</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/978-3-662-05767-4_1</pub-id></element-citation></ref><ref id="B7-toxins-17-00056"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haldenwang</surname><given-names>W.G.</given-names></name>
</person-group><article-title>The sigma factors of <italic toggle="yes">Bacillus subtilis</italic></article-title><source>Microbiol. Rev.</source><year>1995</year><volume>59</volume><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1128/mr.59.1.1-30.1995</pub-id><pub-id pub-id-type="pmid">7708009</pub-id>
</element-citation></ref><ref id="B8-toxins-17-00056"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henriques</surname><given-names>A.O.</given-names></name>
<name><surname>Moran</surname><given-names>C.P.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Structure, assembly, and function of the spore surface layers</article-title><source>Annu. Rev. Microbiol.</source><year>2007</year><volume>61</volume><fpage>555</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.61.080706.093224</pub-id><pub-id pub-id-type="pmid">18035610</pub-id>
</element-citation></ref><ref id="B9-toxins-17-00056"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Bergman</surname><given-names>N.H.</given-names></name>
<name><surname>Thomason</surname><given-names>B.</given-names></name>
<name><surname>Shallom</surname><given-names>S.</given-names></name>
<name><surname>Hazen</surname><given-names>A.</given-names></name>
<name><surname>Crossno</surname><given-names>J.</given-names></name>
<name><surname>Rasko</surname><given-names>D.A.</given-names></name>
<name><surname>Ravel</surname><given-names>J.</given-names></name>
<name><surname>Read</surname><given-names>T.D.</given-names></name>
<name><surname>Peterson</surname><given-names>S.N.</given-names></name>
<etal/>
</person-group><article-title>Formation and composition of the <italic toggle="yes">Bacillus anthracis</italic> endospore</article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>164</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1128/JB.186.1.164-178.2004</pub-id><pub-id pub-id-type="pmid">14679236</pub-id>
</element-citation></ref><ref id="B10-toxins-17-00056"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Camp</surname><given-names>A.H.</given-names></name>
<name><surname>Wang</surname><given-names>A.F.</given-names></name>
<name><surname>Losick</surname><given-names>R.</given-names></name>
</person-group><article-title>A small protein required for the switch from sigmaF to sigmaG during sporulation in <italic toggle="yes">Bacillus subtilis</italic></article-title><source>J. Bacteriol.</source><year>2011</year><volume>193</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1128/JB.00949-10</pub-id><pub-id pub-id-type="pmid">21037003</pub-id>
</element-citation></ref><ref id="B11-toxins-17-00056"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadjifrangiskou</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Koehler</surname><given-names>T.M.</given-names></name>
</person-group><article-title>The alternative sigma factor sigmaH is required for toxin gene expression by <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>1874</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1128/JB.01333-06</pub-id><pub-id pub-id-type="pmid">17189374</pub-id>
</element-citation></ref><ref id="B12-toxins-17-00056"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Lyu</surname><given-names>Y.</given-names></name>
<name><surname>Feng</surname><given-names>E.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Pan</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>SpoVG is Necessary for Sporulation in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>548</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8040548</pub-id><pub-id pub-id-type="pmid">32290166</pub-id>
</element-citation></ref><ref id="B13-toxins-17-00056"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bongiorni</surname><given-names>C.</given-names></name>
<name><surname>Stoessel</surname><given-names>R.</given-names></name>
<name><surname>Perego</surname><given-names>M.</given-names></name>
</person-group><article-title>Negative regulation of <italic toggle="yes">Bacillus anthracis</italic> sporulation by the Spo0E family of phosphatases</article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>2637</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.1128/JB.01798-06</pub-id><pub-id pub-id-type="pmid">17259308</pub-id>
</element-citation></ref><ref id="B14-toxins-17-00056"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liszewski Zilla</surname><given-names>M.</given-names></name>
<name><surname>Lunderberg</surname><given-names>J.M.</given-names></name>
<name><surname>Schneewind</surname><given-names>O.</given-names></name>
<name><surname>Missiakas</surname><given-names>D.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> lcp Genes Support Vegetative Growth, Envelope Assembly, and Spore Formation</article-title><source>J. Bacteriol.</source><year>2015</year><volume>197</volume><fpage>3731</fpage><lpage>3741</lpage><pub-id pub-id-type="doi">10.1128/JB.00656-15</pub-id><pub-id pub-id-type="pmid">26391207</pub-id>
</element-citation></ref><ref id="B15-toxins-17-00056"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>L.K.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Sajid</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Bhaduri</surname><given-names>A.</given-names></name>
<name><surname>Bharadwaj</surname><given-names>M.</given-names></name>
<name><surname>Gandotra</surname><given-names>S.</given-names></name>
<name><surname>Kalia</surname><given-names>V.C.</given-names></name>
<name><surname>Das</surname><given-names>T.K.</given-names></name>
<name><surname>Goel</surname><given-names>A.K.</given-names></name>
<etal/>
</person-group><article-title>clpC operon regulates cell architecture and sporulation in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Environ. Microbiol.</source><year>2015</year><volume>17</volume><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.12548</pub-id><pub-id pub-id-type="pmid">24947607</pub-id>
</element-citation></ref><ref id="B16-toxins-17-00056"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gangwal</surname><given-names>A.</given-names></name>
<name><surname>Sangwan</surname><given-names>N.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Keshavam</surname><given-names>C.C.</given-names></name>
<name><surname>Singh</surname><given-names>L.K.</given-names></name>
<name><surname>Bothra</surname><given-names>A.</given-names></name>
<name><surname>Goel</surname><given-names>A.K.</given-names></name>
<name><surname>Pomerantsev</surname><given-names>A.P.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<etal/>
</person-group><article-title>Role of serine/threonine protein phosphatase PrpN in the life cycle of <italic toggle="yes">Bacillus anthracis</italic></article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1010729</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010729</pub-id><pub-id pub-id-type="pmid">35913993</pub-id>
</element-citation></ref><ref id="B17-toxins-17-00056"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paidhungat</surname><given-names>M.</given-names></name>
<name><surname>Setlow</surname><given-names>B.</given-names></name>
<name><surname>Driks</surname><given-names>A.</given-names></name>
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Characterization of spores of <italic toggle="yes">Bacillus subtilis</italic> which lack dipicolinic acid</article-title><source>J. Bacteriol.</source><year>2000</year><volume>182</volume><fpage>5505</fpage><lpage>5512</lpage><pub-id pub-id-type="doi">10.1128/JB.182.19.5505-5512.2000</pub-id><pub-id pub-id-type="pmid">10986255</pub-id>
</element-citation></ref><ref id="B18-toxins-17-00056"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>E.M.</given-names></name>
<name><surname>Phadke</surname><given-names>N.D.</given-names></name>
<name><surname>Kachman</surname><given-names>M.T.</given-names></name>
<name><surname>Giorno</surname><given-names>R.</given-names></name>
<name><surname>Vazquez</surname><given-names>S.</given-names></name>
<name><surname>Vazquez</surname><given-names>J.A.</given-names></name>
<name><surname>Maddock</surname><given-names>J.R.</given-names></name>
<name><surname>Driks</surname><given-names>A.</given-names></name>
</person-group><article-title>Proteomic analysis of the spore coats of <italic toggle="yes">Bacillus subtilis</italic> and <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Bacteriol.</source><year>2003</year><volume>185</volume><fpage>1443</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1128/JB.185.4.1443-1454.2003</pub-id><pub-id pub-id-type="pmid">12562816</pub-id>
</element-citation></ref><ref id="B19-toxins-17-00056"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deatherage Kaiser</surname><given-names>B.L.</given-names></name>
<name><surname>Wunschel</surname><given-names>D.S.</given-names></name>
<name><surname>Sydor</surname><given-names>M.A.</given-names></name>
<name><surname>Warner</surname><given-names>M.G.</given-names></name>
<name><surname>Wahl</surname><given-names>K.L.</given-names></name>
<name><surname>Hutchison</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Improved proteomic analysis following trichloroacetic acid extraction of <italic toggle="yes">Bacillus anthracis</italic> spore proteins</article-title><source>J. Microbiol. Methods</source><year>2015</year><volume>118</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2015.08.008</pub-id><pub-id pub-id-type="pmid">26295278</pub-id>
</element-citation></ref><ref id="B20-toxins-17-00056"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abhyankar</surname><given-names>W.</given-names></name>
<name><surname>de Koning</surname><given-names>L.J.</given-names></name>
<name><surname>Brul</surname><given-names>S.</given-names></name>
<name><surname>de Koster</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Spore proteomics: The past, present and the future</article-title><source>FEMS Microbiol. Lett.</source><year>2014</year><volume>358</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/1574-6968.12568</pub-id><pub-id pub-id-type="pmid">25110127</pub-id>
</element-citation></ref><ref id="B21-toxins-17-00056"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Spore germination</article-title><source>Curr. Opin. Microbiol.</source><year>2003</year><volume>6</volume><fpage>550</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2003.10.001</pub-id><pub-id pub-id-type="pmid">14662349</pub-id>
</element-citation></ref><ref id="B22-toxins-17-00056"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Driks</surname><given-names>A.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Bacillus anthracis</italic> spore</article-title><source>Mol. Aspects Med.</source><year>2009</year><volume>30</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2009.08.001</pub-id><pub-id pub-id-type="pmid">19683018</pub-id>
</element-citation></ref><ref id="B23-toxins-17-00056"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heffron</surname><given-names>J.D.</given-names></name>
<name><surname>Orsburn</surname><given-names>B.</given-names></name>
<name><surname>Popham</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Roles of germination-specific lytic enzymes CwlJ and SleB in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Bacteriol.</source><year>2009</year><volume>191</volume><fpage>2237</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1128/JB.01598-08</pub-id><pub-id pub-id-type="pmid">19181808</pub-id>
</element-citation></ref><ref id="B24-toxins-17-00056"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aronson</surname><given-names>A.I.</given-names></name>
<name><surname>Fitz-James</surname><given-names>P.</given-names></name>
</person-group><article-title>Structure and morphogenesis of the bacterial spore coat</article-title><source>Bacteriol. Rev.</source><year>1976</year><volume>40</volume><fpage>360</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1128/br.40.2.360-402.1976</pub-id><pub-id pub-id-type="pmid">786255</pub-id>
</element-citation></ref><ref id="B25-toxins-17-00056"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
<name><surname>Sherman</surname><given-names>D.</given-names></name>
<name><surname>Johnson</surname><given-names>F.</given-names></name>
<name><surname>Aronson</surname><given-names>A.I.</given-names></name>
</person-group><article-title>Characterization of a major <italic toggle="yes">Bacillus anthracis</italic> spore coat protein and its role in spore inactivation</article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>2413</fpage><lpage>2417</lpage><pub-id pub-id-type="doi">10.1128/JB.186.8.2413-2417.2004</pub-id><pub-id pub-id-type="pmid">15060044</pub-id>
</element-citation></ref><ref id="B26-toxins-17-00056"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourne</surname><given-names>N.</given-names></name>
<name><surname>FitzJames</surname><given-names>P.C.</given-names></name>
<name><surname>Aronson</surname><given-names>A.I.</given-names></name>
</person-group><article-title>Structural and germination defects of <italic toggle="yes">Bacillus subtilis</italic> spores with altered contents of a spore coat protein</article-title><source>J. Bacteriol.</source><year>1991</year><volume>173</volume><fpage>6618</fpage><lpage>6625</lpage><pub-id pub-id-type="doi">10.1128/jb.173.20.6618-6625.1991</pub-id><pub-id pub-id-type="pmid">1917883</pub-id>
</element-citation></ref><ref id="B27-toxins-17-00056"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernhards</surname><given-names>C.B.</given-names></name>
<name><surname>Popham</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Role of YpeB in cortex hydrolysis during germination of <italic toggle="yes">Bacillus anthracis</italic> spores</article-title><source>J. Bacteriol.</source><year>2014</year><volume>196</volume><fpage>3399</fpage><lpage>3409</lpage><pub-id pub-id-type="doi">10.1128/JB.01899-14</pub-id><pub-id pub-id-type="pmid">25022853</pub-id>
</element-citation></ref><ref id="B28-toxins-17-00056"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Gangwal</surname><given-names>A.</given-names></name>
<name><surname>Sangwan</surname><given-names>N.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Keshavam</surname><given-names>C.C.</given-names></name>
<name><surname>Tyagi</surname><given-names>E.</given-names></name>
<name><surname>Singh</surname><given-names>Y.</given-names></name>
</person-group><article-title>ClpC-Mediated Sporulation Regulation at Engulfment Stage in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Indian J. Microbiol.</source><year>2021</year><volume>61</volume><fpage>170</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/s12088-021-00927-5</pub-id><pub-id pub-id-type="pmid">33927458</pub-id>
</element-citation></ref><ref id="B29-toxins-17-00056"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ireland</surname><given-names>J.A.</given-names></name>
<name><surname>Hanna</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Amino acid- and purine ribonucleoside-induced germination of <italic toggle="yes">Bacillus anthracis</italic> DeltaSterne endospores: GerS mediates responses to aromatic ring structures</article-title><source>J. Bacteriol.</source><year>2002</year><volume>184</volume><fpage>1296</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1128/JB.184.5.1296-1303.2002</pub-id><pub-id pub-id-type="pmid">11844758</pub-id>
</element-citation></ref><ref id="B30-toxins-17-00056"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clements</surname><given-names>M.O.</given-names></name>
<name><surname>Moir</surname><given-names>A.</given-names></name>
</person-group><article-title>Role of the gerI operon of <italic toggle="yes">Bacillus cereus</italic> 569 in the response of spores to germinants</article-title><source>J. Bacteriol.</source><year>1998</year><volume>180</volume><fpage>6729</fpage><lpage>6735</lpage><pub-id pub-id-type="doi">10.1128/JB.180.24.6729-6735.1998</pub-id><pub-id pub-id-type="pmid">9852021</pub-id>
</element-citation></ref><ref id="B31-toxins-17-00056"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>K.D.</given-names></name>
<name><surname>Corfe</surname><given-names>B.M.</given-names></name>
<name><surname>Kemp</surname><given-names>E.H.</given-names></name>
<name><surname>Feavers</surname><given-names>I.M.</given-names></name>
<name><surname>Coote</surname><given-names>P.J.</given-names></name>
<name><surname>Moir</surname><given-names>A.</given-names></name>
</person-group><article-title>Localization of GerAA and GerAC germination proteins in the <italic toggle="yes">Bacillus subtilis</italic> spore</article-title><source>J. Bacteriol.</source><year>2001</year><volume>183</volume><fpage>4317</fpage><lpage>4322</lpage><pub-id pub-id-type="doi">10.1128/JB.183.14.4317-4322.2001</pub-id><pub-id pub-id-type="pmid">11418573</pub-id>
</element-citation></ref><ref id="B32-toxins-17-00056"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carr</surname><given-names>K.A.</given-names></name>
<name><surname>Janes</surname><given-names>B.K.</given-names></name>
<name><surname>Hanna</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Role of the gerP operon in germination and outgrowth of <italic toggle="yes">Bacillus anthracis</italic> spores</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e9128</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/8f1e2a19-cb97-4680-a6b9-40e0116e7842</pub-id><pub-id pub-id-type="pmid">20161744</pub-id>
</element-citation></ref><ref id="B33-toxins-17-00056"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Summer meeting 201&#x02014;When the sleepers wake: The germination of spores of <italic toggle="yes">Bacillus</italic> species</article-title><source>J. Appl. Microbiol.</source><year>2013</year><volume>115</volume><fpage>1251</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1111/jam.12343</pub-id><pub-id pub-id-type="pmid">24102780</pub-id>
</element-citation></ref><ref id="B34-toxins-17-00056"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vepachedu</surname><given-names>V.R.</given-names></name>
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Role of SpoVA proteins in release of dipicolinic acid during germination of <italic toggle="yes">Bacillus subtilis</italic> spores triggered by dodecylamine or lysozyme</article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>1565</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1128/JB.01613-06</pub-id><pub-id pub-id-type="pmid">17158659</pub-id>
</element-citation></ref><ref id="B35-toxins-17-00056"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giebel</surname><given-names>J.D.</given-names></name>
<name><surname>Carr</surname><given-names>K.A.</given-names></name>
<name><surname>Anderson</surname><given-names>E.C.</given-names></name>
<name><surname>Hanna</surname><given-names>P.C.</given-names></name>
</person-group><article-title>The germination-specific lytic enzymes SleB, CwlJ1, and CwlJ2 each contribute to <italic toggle="yes">Bacillus anthracis</italic> spore germination and virulence</article-title><source>J. Bacteriol.</source><year>2009</year><volume>191</volume><fpage>5569</fpage><lpage>5576</lpage><pub-id pub-id-type="doi">10.1128/JB.00408-09</pub-id><pub-id pub-id-type="pmid">19581364</pub-id>
</element-citation></ref><ref id="B36-toxins-17-00056"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Germination of spores of <italic toggle="yes">Bacillus</italic> species: What we know and do not know</article-title><source>J. Bacteriol.</source><year>2014</year><volume>196</volume><fpage>1297</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1128/JB.01455-13</pub-id><pub-id pub-id-type="pmid">24488313</pub-id>
</element-citation></ref><ref id="B37-toxins-17-00056"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>L.</given-names></name>
<name><surname>Sonenshein</surname><given-names>R.L.</given-names></name>
<name><surname>Hoch James</surname><given-names>A.</given-names></name>
</person-group><source>Bacillus subtilis and Other Gram-Positive Bacteria: Biochemistry, Physiology, and Molecular Genetics</source><person-group person-group-type="editor">
<name><surname>Abraham</surname><given-names>R.L.</given-names></name>
<name><surname>Sonenshein</surname><given-names>L.</given-names></name>
<name><surname>Hoch James</surname><given-names>A.</given-names></name>
</person-group><publisher-name>ASM Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B38-toxins-17-00056"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Setlow</surname><given-names>P.</given-names></name>
</person-group><article-title>Mechanisms for the prevention of damage to DNA in spores of <italic toggle="yes">Bacillus</italic> species</article-title><source>Annu. Rev. Microbiol.</source><year>1995</year><volume>49</volume><fpage>29</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1146/annurev.mi.49.100195.000333</pub-id><pub-id pub-id-type="pmid">8561462</pub-id>
</element-citation></ref><ref id="B39-toxins-17-00056"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashique</surname><given-names>S.</given-names></name>
<name><surname>Biswas</surname><given-names>A.</given-names></name>
<name><surname>Mohanto</surname><given-names>S.</given-names></name>
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Hussain</surname><given-names>M.S.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.G.</given-names></name>
<name><surname>Subramaniyan</surname><given-names>V.</given-names></name>
</person-group><article-title>Anthrax: A narrative review</article-title><source>New Microbes New Infect.</source><year>2024</year><volume>62</volume><fpage>101501</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2024.101501</pub-id><pub-id pub-id-type="pmid">39497912</pub-id>
</element-citation></ref><ref id="B40-toxins-17-00056"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bhunia</surname><given-names>A.K.</given-names></name>
</person-group><source>Foodborne Microbial Pathogens</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2018</year></element-citation></ref><ref id="B41-toxins-17-00056"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McKendrick</surname><given-names>D.</given-names></name>
</person-group><article-title>Anthrax and its transmission to humans</article-title><source>Cent. Afr. J. Med.</source><year>1980</year><volume>26</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">7407891</pub-id>
</element-citation></ref><ref id="B42-toxins-17-00056"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doganay</surname><given-names>M.</given-names></name>
<name><surname>Dinc</surname><given-names>G.</given-names></name>
<name><surname>Kutmanova</surname><given-names>A.</given-names></name>
<name><surname>Baillie</surname><given-names>L.</given-names></name>
</person-group><article-title>Human Anthrax: Update of the Diagnosis and Treatment</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><elocation-id>1056</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics13061056</pub-id><pub-id pub-id-type="pmid">36980364</pub-id>
</element-citation></ref><ref id="B43-toxins-17-00056"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doganay</surname><given-names>M.</given-names></name>
<name><surname>Metan</surname><given-names>G.</given-names></name>
<name><surname>Alp</surname><given-names>E.</given-names></name>
</person-group><article-title>A review of cutaneous anthrax and its outcome</article-title><source>J. Infect. Public Health</source><year>2010</year><volume>3</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2010.07.004</pub-id><pub-id pub-id-type="pmid">20869669</pub-id>
</element-citation></ref><ref id="B44-toxins-17-00056"><label>44.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><article-title>Use of Anthrax Vaccine in the United States</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4915a1.htm#:~:text=The%20case%2Dfatality%20rate%20of,1%2C23%2C24).&#x00026;text=The%20intestinal%20form%20of%20anthrax,inflammation%20of%20the%20intestinal%20tract" ext-link-type="uri">https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4915a1.htm#:~:text=The%20case%2Dfatality%20rate%20of,1%2C23%2C24).&#x00026;text=The%20intestinal%20form%20of%20anthrax,inflammation%20of%20the%20intestinal%20tract</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-10">(accessed on 10 January 2025)</date-in-citation></element-citation></ref><ref id="B45-toxins-17-00056"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>CDC Antibiotics</source><publisher-name>CDC</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/anthrax/hcp/antibiotics/index.html" ext-link-type="uri">https://www.cdc.gov/anthrax/hcp/antibiotics/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-21">(accessed on 21 January 2025)</date-in-citation></element-citation></ref><ref id="B46-toxins-17-00056"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zasada</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Injectional anthrax in human: A new face of the old disease</article-title><source>Adv. Clin. Exp. Med.</source><year>2018</year><volume>27</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.17219/acem/68380</pub-id><pub-id pub-id-type="pmid">29533547</pub-id>
</element-citation></ref><ref id="B47-toxins-17-00056"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grunow</surname><given-names>R.</given-names></name>
<name><surname>Klee</surname><given-names>S.R.</given-names></name>
<name><surname>Beyer</surname><given-names>W.</given-names></name>
<name><surname>George</surname><given-names>M.</given-names></name>
<name><surname>Grunow</surname><given-names>D.</given-names></name>
<name><surname>Barduhn</surname><given-names>A.</given-names></name>
<name><surname>Klar</surname><given-names>S.</given-names></name>
<name><surname>Jacob</surname><given-names>D.</given-names></name>
<name><surname>Elschner</surname><given-names>M.</given-names></name>
<name><surname>Sandven</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Anthrax among heroin users in Europe possibly caused by same <italic toggle="yes">Bacillus anthracis</italic> strain since 2000</article-title><source>Eurosurveill</source><year>2013</year><volume>18</volume><fpage>20437</fpage><pub-id pub-id-type="doi">10.2807/ese.18.13.20437-en</pub-id></element-citation></ref><ref id="B48-toxins-17-00056"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katharios-Lanwermeyer</surname><given-names>S.</given-names></name>
<name><surname>Holty</surname><given-names>J.E.</given-names></name>
<name><surname>Person</surname><given-names>M.</given-names></name>
<name><surname>Sejvar</surname><given-names>J.</given-names></name>
<name><surname>Haberling</surname><given-names>D.</given-names></name>
<name><surname>Tubbs</surname><given-names>H.</given-names></name>
<name><surname>Meaney-Delman</surname><given-names>D.</given-names></name>
<name><surname>Pillai</surname><given-names>S.K.</given-names></name>
<name><surname>Hupert</surname><given-names>N.</given-names></name>
<name><surname>Bower</surname><given-names>W.A.</given-names></name>
<etal/>
</person-group><article-title>Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>62</volume><fpage>1537</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw184</pub-id><pub-id pub-id-type="pmid">27025833</pub-id>
</element-citation></ref><ref id="B49-toxins-17-00056"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bozic</surname><given-names>D.</given-names></name>
<name><surname>Zivanovic</surname><given-names>J.</given-names></name>
<name><surname>Zivancevic</surname><given-names>K.</given-names></name>
<name><surname>Baralic</surname><given-names>K.</given-names></name>
<name><surname>Dukic-Cosic</surname><given-names>D.</given-names></name>
</person-group><article-title>Trends in Anti-Tumor Effects of Pseudomonas aeruginosa Mannose-Sensitive-Hemagglutinin (PA-MSHA): An Overview of Positive and Negative Effects</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>524</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16030524</pub-id><pub-id pub-id-type="pmid">38339275</pub-id>
</element-citation></ref><ref id="B50-toxins-17-00056"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Vrentas</surname><given-names>C.</given-names></name>
<name><surname>Pomerantsev</surname><given-names>A.P.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
</person-group><article-title>Anthrax Pathogenesis</article-title><source>Annu. Rev. Microbiol.</source><year>2015</year><volume>69</volume><fpage>185</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-091014-104523</pub-id><pub-id pub-id-type="pmid">26195305</pub-id>
</element-citation></ref><ref id="B51-toxins-17-00056"><label>51.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Bacterial Pathogenesis</article-title><source>Medical Microbiology</source><edition>4th ed.</edition><person-group person-group-type="editor">
<name><surname>Baron</surname><given-names>S.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Galveston, TX, USA</publisher-loc><year>1996</year></element-citation></ref><ref id="B52-toxins-17-00056"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chavarria-Smith</surname><given-names>J.</given-names></name>
<name><surname>Vance</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003452</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003452</pub-id><pub-id pub-id-type="pmid">23818853</pub-id>
</element-citation></ref><ref id="B53-toxins-17-00056"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendenhall</surname><given-names>M.A.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Portley</surname><given-names>M.K.</given-names></name>
<name><surname>O&#x02019;Mard</surname><given-names>D.</given-names></name>
<name><surname>Fattah</surname><given-names>R.</given-names></name>
<name><surname>Szabo</surname><given-names>R.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
<name><surname>Khillan</surname><given-names>J.S.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
</person-group><article-title>Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1464</fpage><lpage>1471</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0782-1</pub-id><pub-id pub-id-type="pmid">32895527</pub-id>
</element-citation></ref><ref id="B54-toxins-17-00056"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wickliffe</surname><given-names>K.E.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
</person-group><article-title>Killing of macrophages by anthrax lethal toxin: Involvement of the N-end rule pathway</article-title><source>Cell Microbiol.</source><year>2008</year><volume>10</volume><fpage>1352</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01131.x</pub-id><pub-id pub-id-type="pmid">18266992</pub-id>
</element-citation></ref><ref id="B55-toxins-17-00056"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Cellular and systemic effects of anthrax lethal toxin and edema toxin</article-title><source>Mol. Aspects Med.</source><year>2009</year><volume>30</volume><fpage>439</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2009.07.003</pub-id><pub-id pub-id-type="pmid">19638283</pub-id>
</element-citation></ref><ref id="B56-toxins-17-00056"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>W.J.</given-names></name>
<name><surname>Guo</surname><given-names>Q.</given-names></name>
</person-group><article-title>The adenylyl cyclase activity of anthrax edema factor</article-title><source>Mol. Aspects Med.</source><year>2009</year><volume>30</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2009.06.001</pub-id><pub-id pub-id-type="pmid">19560485</pub-id>
</element-citation></ref><ref id="B57-toxins-17-00056"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Nestorovich</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Anthrax toxin channel: What we know based on over 30 years of research</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2021</year><volume>1863</volume><elocation-id>183715</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamem.2021.183715</pub-id><pub-id pub-id-type="pmid">34332985</pub-id>
</element-citation></ref><ref id="B58-toxins-17-00056"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>J.A.</given-names></name>
<name><surname>Collier</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Anthrax toxin: Receptor binding, internalization, pore formation, and translocation</article-title><source>Annu. Rev. Biochem.</source><year>2007</year><volume>76</volume><fpage>243</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.103004.142728</pub-id><pub-id pub-id-type="pmid">17335404</pub-id>
</element-citation></ref><ref id="B59-toxins-17-00056"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>Y.</given-names></name>
<name><surname>Klimpel</surname><given-names>K.R.</given-names></name>
<name><surname>Arora</surname><given-names>N.</given-names></name>
<name><surname>Sharma</surname><given-names>M.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>29039</fpage><lpage>29046</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)62010-7</pub-id><pub-id pub-id-type="pmid">7961869</pub-id>
</element-citation></ref><ref id="B60-toxins-17-00056"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Dubey</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Gangwal</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>Y.</given-names></name>
</person-group><article-title>Bacterial Virulence Factors: Secreted for Survival</article-title><source>Indian J. Microbiol.</source><year>2017</year><volume>57</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s12088-016-0625-1</pub-id><pub-id pub-id-type="pmid">28148975</pub-id>
</element-citation></ref><ref id="B61-toxins-17-00056"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pilo</surname><given-names>P.</given-names></name>
<name><surname>Frey</surname><given-names>J.</given-names></name>
</person-group><article-title>Pathogenicity, population genetics and dissemination of <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Infect. Genet. Evol.</source><year>2018</year><volume>64</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2018.06.024</pub-id><pub-id pub-id-type="pmid">29935338</pub-id>
</element-citation></ref><ref id="B62-toxins-17-00056"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Anthrax lethal and edema toxins in anthrax pathogenesis</article-title><source>Trends Microbiol.</source><year>2014</year><volume>22</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2014.02.012</pub-id><pub-id pub-id-type="pmid">24684968</pub-id>
</element-citation></ref><ref id="B63-toxins-17-00056"><label>63.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Anthrax lethal factor</article-title><source>Handbook of Proteolytic Enzymes</source><publisher-name>Elsevier</publisher-name><publisher-loc>London, UK</publisher-loc><year>2004</year><fpage>781</fpage><lpage>783</lpage></element-citation></ref><ref id="B64-toxins-17-00056"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>Z.L.</given-names></name>
<name><surname>Printz</surname><given-names>M.P.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Crown</surname><given-names>D.</given-names></name>
<name><surname>Breen</surname><given-names>L.</given-names></name>
<name><surname>Miller-Randolph</surname><given-names>S.</given-names></name>
<name><surname>Flodman</surname><given-names>P.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
</person-group><article-title>Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1000906</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000906</pub-id><pub-id pub-id-type="pmid">20502689</pub-id>
</element-citation></ref><ref id="B65-toxins-17-00056"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Haines</surname><given-names>D.</given-names></name>
<name><surname>Young</surname><given-names>H.A.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice</article-title><source>J. Clin. Investig.</source><year>2003</year><volume>112</volume><fpage>670</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1172/JCI17991</pub-id><pub-id pub-id-type="pmid">12952916</pub-id>
</element-citation></ref><ref id="B66-toxins-17-00056"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Crown</surname><given-names>D.</given-names></name>
<name><surname>Fattah</surname><given-names>R.J.</given-names></name>
<name><surname>Wein</surname><given-names>A.N.</given-names></name>
<name><surname>Yu</surname><given-names>Z.X.</given-names></name>
<name><surname>Finkel</surname><given-names>T.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Key tissue targets responsible for anthrax-toxin-induced lethality</article-title><source>Nature</source><year>2013</year><volume>501</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nature12510</pub-id><pub-id pub-id-type="pmid">23995686</pub-id>
</element-citation></ref><ref id="B67-toxins-17-00056"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muanprasat</surname><given-names>C.</given-names></name>
<name><surname>Chatsudthipong</surname><given-names>V.</given-names></name>
</person-group><article-title>Cholera: Pathophysiology and emerging therapeutic targets</article-title><source>Future Med. Chem.</source><year>2013</year><volume>5</volume><fpage>781</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.4155/fmc.13.42</pub-id><pub-id pub-id-type="pmid">23651092</pub-id>
</element-citation></ref><ref id="B68-toxins-17-00056"><label>68.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>WHO Cancer</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/health-topics/cancer#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/cancer#tab=tab_1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-21">(accessed on 21 November 2024)</date-in-citation></element-citation></ref><ref id="B69-toxins-17-00056"><label>69.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>WHO Cancer Burden</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services" ext-link-type="uri">https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-21">(accessed on 21 November 2024)</date-in-citation></element-citation></ref><ref id="B70-toxins-17-00056"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Tepper</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Radiation therapy-associated toxicity: Etiology, management, and prevention</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>437</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.3322/caac.21689</pub-id><pub-id pub-id-type="pmid">34255347</pub-id>
</element-citation></ref><ref id="B71-toxins-17-00056"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anand</surname><given-names>U.</given-names></name>
<name><surname>Dey</surname><given-names>A.</given-names></name>
<name><surname>Chandel</surname><given-names>A.K.S.</given-names></name>
<name><surname>Sanyal</surname><given-names>R.</given-names></name>
<name><surname>Mishra</surname><given-names>A.</given-names></name>
<name><surname>Pandey</surname><given-names>D.K.</given-names></name>
<name><surname>De Falco</surname><given-names>V.</given-names></name>
<name><surname>Upadhyay</surname><given-names>A.</given-names></name>
<name><surname>Kandimalla</surname><given-names>R.</given-names></name>
<name><surname>Chaudhary</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics</article-title><source>Genes. Dis.</source><year>2023</year><volume>10</volume><fpage>1367</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2022.02.007</pub-id><pub-id pub-id-type="pmid">37397557</pub-id>
</element-citation></ref><ref id="B72-toxins-17-00056"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wintrobe</surname><given-names>M.M.</given-names></name>
<name><surname>Huguley</surname><given-names>C.M.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Nitrogen-mustard therapy for Hodgkin&#x02019;s disease, lymphosarcoma, the leukemias, and other disorders</article-title><source>Cancer</source><year>1948</year><volume>1</volume><fpage>357</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(194809)1:3&#x0003c;357::AID-CNCR2820010303&#x0003e;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">18887904</pub-id>
</element-citation></ref><ref id="B73-toxins-17-00056"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasima</surname><given-names>N.</given-names></name>
<name><surname>Ozpolat</surname><given-names>B.</given-names></name>
</person-group><article-title>Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1509</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.467</pub-id><pub-id pub-id-type="pmid">25375374</pub-id>
</element-citation></ref><ref id="B74-toxins-17-00056"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>J.</given-names></name>
<name><surname>Gulati</surname><given-names>M.</given-names></name>
<name><surname>Jha</surname><given-names>N.K.</given-names></name>
<name><surname>Disouza</surname><given-names>J.</given-names></name>
<name><surname>Patravale</surname><given-names>V.</given-names></name>
<name><surname>Dua</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Recent advances in developing polymeric micelles for treating cancer: Breakthroughs and bottlenecks in their clinical translation</article-title><source>Drug Discov. Today</source><year>2022</year><volume>27</volume><fpage>1495</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2022.02.005</pub-id><pub-id pub-id-type="pmid">35158056</pub-id>
</element-citation></ref><ref id="B75-toxins-17-00056"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nasibullin</surname><given-names>I.</given-names></name>
<name><surname>Smirnov</surname><given-names>I.</given-names></name>
<name><surname>Ahmadi</surname><given-names>P.</given-names></name>
<name><surname>Vong</surname><given-names>K.</given-names></name>
<name><surname>Kurbangalieva</surname><given-names>A.</given-names></name>
<name><surname>Tanaka</surname><given-names>K.</given-names></name>
</person-group><article-title>Synthetic prodrug design enables biocatalytic activation in mice to elicit tumor growth suppression</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27804-5</pub-id><pub-id pub-id-type="pmid">35013295</pub-id>
</element-citation></ref><ref id="B76-toxins-17-00056"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahn</surname><given-names>M.J.</given-names></name>
<name><surname>Lee</surname><given-names>K.H.</given-names></name>
<name><surname>Ahn</surname><given-names>J.I.</given-names></name>
<name><surname>Yu</surname><given-names>D.H.</given-names></name>
<name><surname>Lee</surname><given-names>H.S.</given-names></name>
<name><surname>Choi</surname><given-names>J.H.</given-names></name>
<name><surname>Jang</surname><given-names>J.S.</given-names></name>
<name><surname>Bae</surname><given-names>J.M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.S.</given-names></name>
</person-group><article-title>The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray</article-title><source>Cancer Res. Treat.</source><year>2004</year><volume>36</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.4143/crt.2004.36.1.43</pub-id><pub-id pub-id-type="pmid">20396564</pub-id>
</element-citation></ref><ref id="B77-toxins-17-00056"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pommier</surname><given-names>Y.</given-names></name>
<name><surname>Leo</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Marchand</surname><given-names>C.</given-names></name>
</person-group><article-title>DNA topoisomerases and their poisoning by anticancer and antibacterial drugs</article-title><source>Chem. Biol.</source><year>2010</year><volume>17</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2010.04.012</pub-id><pub-id pub-id-type="pmid">20534341</pub-id>
</element-citation></ref><ref id="B78-toxins-17-00056"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leu</surname><given-names>J.I.</given-names></name>
<name><surname>Pimkina</surname><given-names>J.</given-names></name>
<name><surname>Pandey</surname><given-names>P.</given-names></name>
<name><surname>Murphy</surname><given-names>M.E.</given-names></name>
<name><surname>George</surname><given-names>D.L.</given-names></name>
</person-group><article-title>HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells</article-title><source>Mol. Cancer Res.</source><year>2011</year><volume>9</volume><fpage>936</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-11-0019</pub-id><pub-id pub-id-type="pmid">21636681</pub-id>
</element-citation></ref><ref id="B79-toxins-17-00056"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selimovic</surname><given-names>D.</given-names></name>
<name><surname>Porzig</surname><given-names>B.B.</given-names></name>
<name><surname>El-Khattouti</surname><given-names>A.</given-names></name>
<name><surname>Badura</surname><given-names>H.E.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
<name><surname>Ghanjati</surname><given-names>F.</given-names></name>
<name><surname>Santourlidis</surname><given-names>S.</given-names></name>
<name><surname>Haikel</surname><given-names>Y.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
</person-group><article-title>Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells</article-title><source>Cell. Signal.</source><year>2013</year><volume>25</volume><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2012.10.004</pub-id><pub-id pub-id-type="pmid">23079083</pub-id>
</element-citation></ref><ref id="B80-toxins-17-00056"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taymaz-Nikerel</surname><given-names>H.</given-names></name>
<name><surname>Karabekmez</surname><given-names>M.E.</given-names></name>
<name><surname>Eraslan</surname><given-names>S.</given-names></name>
<name><surname>Kirdar</surname><given-names>B.</given-names></name>
</person-group><article-title>Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>13672</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-31939-9</pub-id><pub-id pub-id-type="pmid">30209405</pub-id>
</element-citation></ref><ref id="B81-toxins-17-00056"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marquez-Lopez</surname><given-names>A.</given-names></name>
<name><surname>Fanarraga</surname><given-names>M.L.</given-names></name>
</person-group><article-title>AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>11227</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241311227</pub-id><pub-id pub-id-type="pmid">37446406</pub-id>
</element-citation></ref><ref id="B82-toxins-17-00056"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreitman</surname><given-names>R.J.</given-names></name>
<name><surname>Pastan</surname><given-names>I.</given-names></name>
</person-group><article-title>Immunotoxins: From Design to Clinical Application</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1696</elocation-id><pub-id pub-id-type="doi">10.3390/biom11111696</pub-id><pub-id pub-id-type="pmid">34827694</pub-id>
</element-citation></ref><ref id="B83-toxins-17-00056"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>St Croix</surname><given-names>B.</given-names></name>
<name><surname>Rago</surname><given-names>C.</given-names></name>
<name><surname>Velculescu</surname><given-names>V.</given-names></name>
<name><surname>Traverso</surname><given-names>G.</given-names></name>
<name><surname>Romans</surname><given-names>K.E.</given-names></name>
<name><surname>Montgomery</surname><given-names>E.</given-names></name>
<name><surname>Lal</surname><given-names>A.</given-names></name>
<name><surname>Riggins</surname><given-names>G.J.</given-names></name>
<name><surname>Lengauer</surname><given-names>C.</given-names></name>
<name><surname>Vogelstein</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Genes expressed in human tumor endothelium</article-title><source>Science</source><year>2000</year><volume>289</volume><fpage>1197</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1126/science.289.5482.1197</pub-id><pub-id pub-id-type="pmid">10947988</pub-id>
</element-citation></ref><ref id="B84-toxins-17-00056"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carson-Walter</surname><given-names>E.B.</given-names></name>
<name><surname>Watkins</surname><given-names>D.N.</given-names></name>
<name><surname>Nanda</surname><given-names>A.</given-names></name>
<name><surname>Vogelstein</surname><given-names>B.</given-names></name>
<name><surname>Kinzler</surname><given-names>K.W.</given-names></name>
<name><surname>St Croix</surname><given-names>B.</given-names></name>
</person-group><article-title>Cell surface tumor endothelial markers are conserved in mice and humans</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>6649</fpage><lpage>6655</lpage><pub-id pub-id-type="pmid">11559528</pub-id>
</element-citation></ref><ref id="B85-toxins-17-00056"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bell</surname><given-names>S.E.</given-names></name>
<name><surname>Mavila</surname><given-names>A.</given-names></name>
<name><surname>Salazar</surname><given-names>R.</given-names></name>
<name><surname>Bayless</surname><given-names>K.J.</given-names></name>
<name><surname>Kanagala</surname><given-names>S.</given-names></name>
<name><surname>Maxwell</surname><given-names>S.A.</given-names></name>
<name><surname>Davis</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Differential gene expression during capillary morphogenesis in 3D collagen matrices: Regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling</article-title><source>J. Cell Sci.</source><year>2001</year><volume>114</volume><fpage>2755</fpage><lpage>2773</lpage><pub-id pub-id-type="doi">10.1242/jcs.114.15.2755</pub-id><pub-id pub-id-type="pmid">11683410</pub-id>
</element-citation></ref><ref id="B86-toxins-17-00056"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reeves</surname><given-names>C.V.</given-names></name>
<name><surname>Dufraine</surname><given-names>J.</given-names></name>
<name><surname>Young</surname><given-names>J.A.</given-names></name>
<name><surname>Kitajewski</surname><given-names>J.</given-names></name>
</person-group><article-title>Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>789</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.383</pub-id><pub-id pub-id-type="pmid">19901963</pub-id>
</element-citation></ref><ref id="B87-toxins-17-00056"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cryan</surname><given-names>L.M.</given-names></name>
<name><surname>Rogers</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy</article-title><source>Front. Biosci.</source><year>2011</year><volume>16</volume><fpage>1574</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.2741/3806</pub-id><pub-id pub-id-type="pmid">21196249</pub-id>
</element-citation></ref><ref id="B88-toxins-17-00056"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Schubert</surname><given-names>R.L.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Anthrax toxin: Structures, functions and tumour targeting</article-title><source>Expert Opin. Biol. Ther.</source><year>2003</year><volume>3</volume><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1517/14712598.3.5.843</pub-id><pub-id pub-id-type="pmid">12880383</pub-id>
</element-citation></ref><ref id="B89-toxins-17-00056"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Netzel-Arnett</surname><given-names>S.</given-names></name>
<name><surname>Birkedal-Hansen</surname><given-names>H.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin</article-title><source>Cancer Res.</source><year>2000</year><volume>60</volume><fpage>6061</fpage><lpage>6067</lpage><pub-id pub-id-type="pmid">11085528</pub-id>
</element-citation></ref><ref id="B90-toxins-17-00056"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>17976</fpage><lpage>17984</lpage><pub-id pub-id-type="doi">10.1074/jbc.M011085200</pub-id><pub-id pub-id-type="pmid">11278833</pub-id>
</element-citation></ref><ref id="B91-toxins-17-00056"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Aaronson</surname><given-names>H.</given-names></name>
<name><surname>Mitola</surname><given-names>D.J.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
</person-group><article-title>Potent antitumor activity of a urokinase-activated engineered anthrax toxin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>657</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1073/pnas.0236849100</pub-id><pub-id pub-id-type="pmid">12525700</pub-id>
</element-citation></ref><ref id="B92-toxins-17-00056"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Redeye</surname><given-names>V.</given-names></name>
<name><surname>Kuremsky</surname><given-names>J.G.</given-names></name>
<name><surname>Kuhnen</surname><given-names>M.</given-names></name>
<name><surname>Molinolo</surname><given-names>A.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin</article-title><source>Nat. Biotechnol.</source><year>2005</year><volume>23</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1038/nbt1091</pub-id><pub-id pub-id-type="pmid">15895075</pub-id>
</element-citation></ref><ref id="B93-toxins-17-00056"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schafer</surname><given-names>J.M.</given-names></name>
<name><surname>Peters</surname><given-names>D.E.</given-names></name>
<name><surname>Morley</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Molinolo</surname><given-names>A.A.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Bugge</surname><given-names>T.H.</given-names></name>
</person-group><article-title>Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e20532</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020532</pub-id><pub-id pub-id-type="pmid">21655226</pub-id>
</element-citation></ref><ref id="B94-toxins-17-00056"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>D.D.</given-names></name>
<name><surname>Fattah</surname><given-names>R.J.</given-names></name>
<name><surname>Crown</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Fischer</surname><given-names>E.R.</given-names></name>
<name><surname>Hansen</surname><given-names>B.T.</given-names></name>
<name><surname>Ghirlando</surname><given-names>R.</given-names></name>
<name><surname>Nestorovich</surname><given-names>E.M.</given-names></name>
<etal/>
</person-group><article-title>Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>9058</fpage><lpage>9065</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.452110</pub-id><pub-id pub-id-type="pmid">23393143</pub-id>
</element-citation></ref><ref id="B95-toxins-17-00056"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stetler-Stevenson</surname><given-names>W.G.</given-names></name>
</person-group><article-title>Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention</article-title><source>J. Clin. Investig.</source><year>1999</year><volume>103</volume><fpage>1237</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1172/JCI6870</pub-id><pub-id pub-id-type="pmid">10225966</pub-id>
</element-citation></ref><ref id="B96-toxins-17-00056"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stetler-Stevenson</surname><given-names>W.G.</given-names></name>
<name><surname>Aznavoorian</surname><given-names>S.</given-names></name>
<name><surname>Liotta</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Tumor cell interactions with the extracellular matrix during invasion and metastasis</article-title><source>Annu. Rev. Cell Biol.</source><year>1993</year><volume>9</volume><fpage>541</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1146/annurev.cb.09.110193.002545</pub-id><pub-id pub-id-type="pmid">8280471</pub-id>
</element-citation></ref><ref id="B97-toxins-17-00056"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dano</surname><given-names>K.</given-names></name>
<name><surname>Romer</surname><given-names>J.</given-names></name>
<name><surname>Nielsen</surname><given-names>B.S.</given-names></name>
<name><surname>Bjorn</surname><given-names>S.</given-names></name>
<name><surname>Pyke</surname><given-names>C.</given-names></name>
<name><surname>Rygaard</surname><given-names>J.</given-names></name>
<name><surname>Lund</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Cancer invasion and tissue remodeling-cooperation of protease systems and cell types</article-title><source>APMIS</source><year>1999</year><volume>107</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1699-0463.1999.tb01534.x</pub-id><pub-id pub-id-type="pmid">10190288</pub-id>
</element-citation></ref><ref id="B98-toxins-17-00056"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duesbery</surname><given-names>N.S.</given-names></name>
<name><surname>Webb</surname><given-names>C.P.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Gordon</surname><given-names>V.M.</given-names></name>
<name><surname>Klimpel</surname><given-names>K.R.</given-names></name>
<name><surname>Copeland</surname><given-names>T.D.</given-names></name>
<name><surname>Ahn</surname><given-names>N.G.</given-names></name>
<name><surname>Oskarsson</surname><given-names>M.K.</given-names></name>
<name><surname>Fukasawa</surname><given-names>K.</given-names></name>
<name><surname>Paull</surname><given-names>K.D.</given-names></name>
<etal/>
</person-group><article-title>Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor</article-title><source>Science</source><year>1998</year><volume>280</volume><fpage>734</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1126/science.280.5364.734</pub-id><pub-id pub-id-type="pmid">9563949</pub-id>
</element-citation></ref><ref id="B99-toxins-17-00056"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vitale</surname><given-names>G.</given-names></name>
<name><surname>Pellizzari</surname><given-names>R.</given-names></name>
<name><surname>Recchi</surname><given-names>C.</given-names></name>
<name><surname>Napolitani</surname><given-names>G.</given-names></name>
<name><surname>Mock</surname><given-names>M.</given-names></name>
<name><surname>Montecucco</surname><given-names>C.</given-names></name>
</person-group><article-title>Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages</article-title><source>J. Appl. Microbiol.</source><year>1999</year><volume>87</volume><elocation-id>288</elocation-id><pub-id pub-id-type="doi">10.1046/j.1365-2672.1999.00893.x</pub-id><pub-id pub-id-type="pmid">10475970</pub-id>
</element-citation></ref><ref id="B100-toxins-17-00056"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samatar</surname><given-names>A.A.</given-names></name>
<name><surname>Poulikakos</surname><given-names>P.I.</given-names></name>
</person-group><article-title>Targeting RAS-ERK signalling in cancer: Promises and challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2014</year><volume>13</volume><fpage>928</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/nrd4281</pub-id><pub-id pub-id-type="pmid">25435214</pub-id>
</element-citation></ref><ref id="B101-toxins-17-00056"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aktories</surname><given-names>K.</given-names></name>
</person-group><article-title>Treatment of ovarian cancer with modified anthrax toxin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2210179119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2210179119</pub-id><pub-id pub-id-type="pmid">35917343</pub-id>
</element-citation></ref><ref id="B102-toxins-17-00056"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Chami</surname><given-names>D.</given-names></name>
<name><surname>Al Haddad</surname><given-names>M.</given-names></name>
<name><surname>Abi-Habib</surname><given-names>R.</given-names></name>
<name><surname>El-Sibai</surname><given-names>M.</given-names></name>
</person-group><article-title>Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases</article-title><source>Oncol. Lett.</source><year>2021</year><volume>21</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.3892/ol.2020.12424</pub-id><pub-id pub-id-type="pmid">33552281</pub-id>
</element-citation></ref><ref id="B103-toxins-17-00056"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCluskey</surname><given-names>A.J.</given-names></name>
<name><surname>Olive</surname><given-names>A.J.</given-names></name>
<name><surname>Starnbach</surname><given-names>M.N.</given-names></name>
<name><surname>Collier</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen</article-title><source>Mol. Oncol.</source><year>2013</year><volume>7</volume><fpage>440</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2012.12.003</pub-id><pub-id pub-id-type="pmid">23290417</pub-id>
</element-citation></ref><ref id="B104-toxins-17-00056"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berchuck</surname><given-names>A.</given-names></name>
<name><surname>Kamel</surname><given-names>A.</given-names></name>
<name><surname>Whitaker</surname><given-names>R.</given-names></name>
<name><surname>Kerns</surname><given-names>B.</given-names></name>
<name><surname>Olt</surname><given-names>G.</given-names></name>
<name><surname>Kinney</surname><given-names>R.</given-names></name>
<name><surname>Soper</surname><given-names>J.T.</given-names></name>
<name><surname>Dodge</surname><given-names>R.</given-names></name>
<name><surname>Clarke-Pearson</surname><given-names>D.L.</given-names></name>
<name><surname>Marks</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer</article-title><source>Cancer Res.</source><year>1990</year><volume>50</volume><fpage>4087</fpage><lpage>4091</lpage><pub-id pub-id-type="pmid">1972347</pub-id>
</element-citation></ref><ref id="B105-toxins-17-00056"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gravalos</surname><given-names>C.</given-names></name>
<name><surname>Jimeno</surname><given-names>A.</given-names></name>
</person-group><article-title>HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target</article-title><source>Ann. Oncol.</source><year>2008</year><volume>19</volume><fpage>1523</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn169</pub-id><pub-id pub-id-type="pmid">18441328</pub-id>
</element-citation></ref><ref id="B106-toxins-17-00056"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slamon</surname><given-names>D.J.</given-names></name>
<name><surname>Godolphin</surname><given-names>W.</given-names></name>
<name><surname>Jones</surname><given-names>L.A.</given-names></name>
<name><surname>Holt</surname><given-names>J.A.</given-names></name>
<name><surname>Wong</surname><given-names>S.G.</given-names></name>
<name><surname>Keith</surname><given-names>D.E.</given-names></name>
<name><surname>Levin</surname><given-names>W.J.</given-names></name>
<name><surname>Stuart</surname><given-names>S.G.</given-names></name>
<name><surname>Udove</surname><given-names>J.</given-names></name>
<name><surname>Ullrich</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title><source>Science</source><year>1989</year><volume>244</volume><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1126/science.2470152</pub-id><pub-id pub-id-type="pmid">2470152</pub-id>
</element-citation></ref><ref id="B107-toxins-17-00056"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arteaga</surname><given-names>C.L.</given-names></name>
<name><surname>Sliwkowski</surname><given-names>M.X.</given-names></name>
<name><surname>Osborne</surname><given-names>C.K.</given-names></name>
<name><surname>Perez</surname><given-names>E.A.</given-names></name>
<name><surname>Puglisi</surname><given-names>F.</given-names></name>
<name><surname>Gianni</surname><given-names>L.</given-names></name>
</person-group><article-title>Treatment of HER2-positive breast cancer: Current status and future perspectives</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2011</year><volume>9</volume><fpage>16</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.177</pub-id><pub-id pub-id-type="pmid">22124364</pub-id>
</element-citation></ref><ref id="B108-toxins-17-00056"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loftis</surname><given-names>A.R.</given-names></name>
<name><surname>Santos</surname><given-names>M.S.</given-names></name>
<name><surname>Truex</surname><given-names>N.L.</given-names></name>
<name><surname>Biancucci</surname><given-names>M.</given-names></name>
<name><surname>Satchell</surname><given-names>K.J.F.</given-names></name>
<name><surname>Pentelute</surname><given-names>B.L.</given-names></name>
</person-group><article-title>Anthrax Protective Antigen Retargeted with Single-Chain Variable Fragments Delivers Enzymes to Pancreatic Cancer Cells</article-title><source>Chembiochem</source><year>2020</year><volume>21</volume><fpage>2772</fpage><lpage>2776</lpage><pub-id pub-id-type="doi">10.1002/cbic.202000201</pub-id><pub-id pub-id-type="pmid">32369652</pub-id>
</element-citation></ref><ref id="B109-toxins-17-00056"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>E.H.</given-names></name>
<name><surname>Krebs</surname><given-names>E.G.</given-names></name>
</person-group><article-title>Conversion of phosphorylase b to phosphorylase a in muscle extracts</article-title><source>J. Biol. Chem.</source><year>1955</year><volume>216</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)52289-X</pub-id><pub-id pub-id-type="pmid">13252012</pub-id>
</element-citation></ref><ref id="B110-toxins-17-00056"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ubersax</surname><given-names>J.A.</given-names></name>
<name><surname>Ferrell</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Mechanisms of specificity in protein phosphorylation</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2007</year><volume>8</volume><fpage>530</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nrm2203</pub-id><pub-id pub-id-type="pmid">17585314</pub-id>
</element-citation></ref><ref id="B111-toxins-17-00056"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dale</surname><given-names>J.L.</given-names></name>
<name><surname>Raynor</surname><given-names>M.J.</given-names></name>
<name><surname>Ty</surname><given-names>M.C.</given-names></name>
<name><surname>Hadjifrangiskou</surname><given-names>M.</given-names></name>
<name><surname>Koehler</surname><given-names>T.M.</given-names></name>
</person-group><article-title>A Dual Role for the <italic toggle="yes">Bacillus anthracis</italic> Master Virulence Regulator AtxA: Control of Sporulation and Anthrax Toxin Production</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>482</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.00482</pub-id><pub-id pub-id-type="pmid">29599764</pub-id>
</element-citation></ref><ref id="B112-toxins-17-00056"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furuta</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>C.</given-names></name>
<name><surname>Zorigt</surname><given-names>T.</given-names></name>
<name><surname>Paudel</surname><given-names>A.</given-names></name>
<name><surname>Izumi</surname><given-names>S.</given-names></name>
<name><surname>Tsujinouchi</surname><given-names>M.</given-names></name>
<name><surname>Shimizu</surname><given-names>T.</given-names></name>
<name><surname>Meijer</surname><given-names>W.G.</given-names></name>
<name><surname>Higashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Direct Regulons of AtxA, the Master Virulence Regulator of <italic toggle="yes">Bacillus anthracis</italic></article-title><source>mSystems</source><year>2021</year><volume>6</volume><fpage>e0029121</fpage><pub-id pub-id-type="doi">10.1128/msystems.00291-21</pub-id><pub-id pub-id-type="pmid">34282944</pub-id>
</element-citation></ref><ref id="B113-toxins-17-00056"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCall</surname><given-names>R.M.</given-names></name>
<name><surname>Sievers</surname><given-names>M.E.</given-names></name>
<name><surname>Fattah</surname><given-names>R.</given-names></name>
<name><surname>Ghirlando</surname><given-names>R.</given-names></name>
<name><surname>Pomerantsev</surname><given-names>A.P.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> Virulence Regulator AtxA Binds Specifically to the pagA Promoter Region</article-title><source>J. Bacteriol.</source><year>2019</year><volume>201</volume><fpage>e00569-19</fpage><pub-id pub-id-type="doi">10.1128/JB.00569-19</pub-id><pub-id pub-id-type="pmid">31570528</pub-id>
</element-citation></ref><ref id="B114-toxins-17-00056"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hammerstrom</surname><given-names>T.G.</given-names></name>
<name><surname>Horton</surname><given-names>L.B.</given-names></name>
<name><surname>Swick</surname><given-names>M.C.</given-names></name>
<name><surname>Joachimiak</surname><given-names>A.</given-names></name>
<name><surname>Osipiuk</surname><given-names>J.</given-names></name>
<name><surname>Koehler</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Crystal structure of <italic toggle="yes">Bacillus anthracis</italic> virulence regulator AtxA and effects of phosphorylated histidines on multimerization and activity</article-title><source>Mol. Microbiol.</source><year>2015</year><volume>95</volume><fpage>426</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1111/mmi.12867</pub-id><pub-id pub-id-type="pmid">25402841</pub-id>
</element-citation></ref><ref id="B115-toxins-17-00056"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsvetanova</surname><given-names>B.</given-names></name>
<name><surname>Wilson</surname><given-names>A.C.</given-names></name>
<name><surname>Bongiorni</surname><given-names>C.</given-names></name>
<name><surname>Chiang</surname><given-names>C.</given-names></name>
<name><surname>Hoch</surname><given-names>J.A.</given-names></name>
<name><surname>Perego</surname><given-names>M.</given-names></name>
</person-group><article-title>Opposing effects of histidine phosphorylation regulate the AtxA virulence transcription factor in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Mol. Microbiol.</source><year>2007</year><volume>63</volume><fpage>644</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05543.x</pub-id><pub-id pub-id-type="pmid">17302798</pub-id>
</element-citation></ref><ref id="B116-toxins-17-00056"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pokorzynski</surname><given-names>N.D.</given-names></name>
<name><surname>Groisman</surname><given-names>E.A.</given-names></name>
</person-group><article-title>How Bacterial Pathogens Coordinate Appetite with Virulence</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2023</year><volume>87</volume><elocation-id>e0019822</elocation-id><pub-id pub-id-type="doi">10.1128/mmbr.00198-22</pub-id><pub-id pub-id-type="pmid">37358444</pub-id>
</element-citation></ref><ref id="B117-toxins-17-00056"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poncet</surname><given-names>S.</given-names></name>
<name><surname>Milohanic</surname><given-names>E.</given-names></name>
<name><surname>Maze</surname><given-names>A.</given-names></name>
<name><surname>Abdallah</surname><given-names>J.N.</given-names></name>
<name><surname>Ake</surname><given-names>F.</given-names></name>
<name><surname>Larribe</surname><given-names>M.</given-names></name>
<name><surname>Deghmane</surname><given-names>A.E.</given-names></name>
<name><surname>Taha</surname><given-names>M.K.</given-names></name>
<name><surname>Dozot</surname><given-names>M.</given-names></name>
<name><surname>De Bolle</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Correlations between carbon metabolism and virulence in bacteria</article-title><source>Contrib. Microbiol.</source><year>2009</year><volume>16</volume><fpage>88</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1159/000219374</pub-id><pub-id pub-id-type="pmid">19494580</pub-id>
</element-citation></ref><ref id="B118-toxins-17-00056"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bier</surname><given-names>N.</given-names></name>
<name><surname>Hammerstrom</surname><given-names>T.G.</given-names></name>
<name><surname>Koehler</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Influence of the phosphoenolpyruvate:carbohydrate phosphotransferase system on toxin gene expression and virulence in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Mol. Microbiol.</source><year>2020</year><volume>113</volume><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/mmi.14413</pub-id><pub-id pub-id-type="pmid">31667937</pub-id>
</element-citation></ref><ref id="B119-toxins-17-00056"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shakir</surname><given-names>S.M.</given-names></name>
<name><surname>Bryant</surname><given-names>K.M.</given-names></name>
<name><surname>Larabee</surname><given-names>J.L.</given-names></name>
<name><surname>Hamm</surname><given-names>E.E.</given-names></name>
<name><surname>Lovchik</surname><given-names>J.</given-names></name>
<name><surname>Lyons</surname><given-names>C.R.</given-names></name>
<name><surname>Ballard</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Regulatory interactions of a virulence-associated serine/threonine phosphatase-kinase pair in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Bacteriol.</source><year>2010</year><volume>192</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1128/JB.01221-09</pub-id><pub-id pub-id-type="pmid">19915022</pub-id>
</element-citation></ref><ref id="B120-toxins-17-00056"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chateau</surname><given-names>A.</given-names></name>
<name><surname>van Schaik</surname><given-names>W.</given-names></name>
<name><surname>Six</surname><given-names>A.</given-names></name>
<name><surname>Aucher</surname><given-names>W.</given-names></name>
<name><surname>Fouet</surname><given-names>A.</given-names></name>
</person-group><article-title>CodY regulation is required for full virulence and heme iron acquisition in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>FASEB J.</source><year>2011</year><volume>25</volume><fpage>4445</fpage><lpage>4456</lpage><pub-id pub-id-type="doi">10.1096/fj.11-188912</pub-id><pub-id pub-id-type="pmid">21911592</pub-id>
</element-citation></ref><ref id="B121-toxins-17-00056"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Schaik</surname><given-names>W.</given-names></name>
<name><surname>Chateau</surname><given-names>A.</given-names></name>
<name><surname>Dillies</surname><given-names>M.A.</given-names></name>
<name><surname>Coppee</surname><given-names>J.Y.</given-names></name>
<name><surname>Sonenshein</surname><given-names>A.L.</given-names></name>
<name><surname>Fouet</surname><given-names>A.</given-names></name>
</person-group><article-title>The global regulator CodY regulates toxin gene expression in <italic toggle="yes">Bacillus anthracis</italic> and is required for full virulence</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>4437</fpage><lpage>4445</lpage><pub-id pub-id-type="doi">10.1128/IAI.00716-09</pub-id><pub-id pub-id-type="pmid">19651859</pub-id>
</element-citation></ref><ref id="B122-toxins-17-00056"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buschiazzo</surname><given-names>A.</given-names></name>
<name><surname>Trajtenberg</surname><given-names>F.</given-names></name>
</person-group><article-title>Two-Component Sensing and Regulation: How Do Histidine Kinases Talk with Response Regulators at the Molecular Level?</article-title><source>Annu. Rev. Microbiol.</source><year>2019</year><volume>73</volume><fpage>507</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-091018-054627</pub-id><pub-id pub-id-type="pmid">31226026</pub-id>
</element-citation></ref><ref id="B123-toxins-17-00056"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capra</surname><given-names>E.J.</given-names></name>
<name><surname>Laub</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Evolution of two-component signal transduction systems</article-title><source>Annu. Rev. Microbiol.</source><year>2012</year><volume>66</volume><fpage>325</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-092611-150039</pub-id><pub-id pub-id-type="pmid">22746333</pub-id>
</element-citation></ref><ref id="B124-toxins-17-00056"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wuichet</surname><given-names>K.</given-names></name>
<name><surname>Cantwell</surname><given-names>B.J.</given-names></name>
<name><surname>Zhulin</surname><given-names>I.B.</given-names></name>
</person-group><article-title>Evolution and phyletic distribution of two-component signal transduction systems</article-title><source>Curr. Opin. Microbiol.</source><year>2010</year><volume>13</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2009.12.011</pub-id><pub-id pub-id-type="pmid">20133179</pub-id>
</element-citation></ref><ref id="B125-toxins-17-00056"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laut</surname><given-names>C.L.</given-names></name>
<name><surname>Leasure</surname><given-names>C.S.</given-names></name>
<name><surname>Pi</surname><given-names>H.</given-names></name>
<name><surname>Carlin</surname><given-names>S.M.</given-names></name>
<name><surname>Chu</surname><given-names>M.L.</given-names></name>
<name><surname>Hillebrand</surname><given-names>G.H.</given-names></name>
<name><surname>Lin</surname><given-names>H.K.</given-names></name>
<name><surname>Yi</surname><given-names>X.I.</given-names></name>
<name><surname>Stauff</surname><given-names>D.L.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
</person-group><article-title>DnaJ and ClpX Are Required for HitRS and HssRS Two-Component System Signaling in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Infect. Immun.</source><year>2022</year><volume>90</volume><fpage>e0056021</fpage><pub-id pub-id-type="doi">10.1128/IAI.00560-21</pub-id><pub-id pub-id-type="pmid">34748369</pub-id>
</element-citation></ref><ref id="B126-toxins-17-00056"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laut</surname><given-names>C.L.</given-names></name>
<name><surname>Perry</surname><given-names>W.J.</given-names></name>
<name><surname>Metzger</surname><given-names>A.L.</given-names></name>
<name><surname>Weiss</surname><given-names>A.</given-names></name>
<name><surname>Stauff</surname><given-names>D.L.</given-names></name>
<name><surname>Walker</surname><given-names>S.</given-names></name>
<name><surname>Caprioli</surname><given-names>R.M.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> Responds to Targocil-Induced Envelope Damage through EdsRS Activation of Cardiolipin Synthesis</article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e03375-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.03375-19</pub-id><pub-id pub-id-type="pmid">32234818</pub-id>
</element-citation></ref><ref id="B127-toxins-17-00056"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pi</surname><given-names>H.</given-names></name>
<name><surname>Chu</surname><given-names>M.L.</given-names></name>
<name><surname>Ivan</surname><given-names>S.J.</given-names></name>
<name><surname>Latario</surname><given-names>C.J.</given-names></name>
<name><surname>Toth</surname><given-names>A.M.</given-names></name>
<name><surname>Carlin</surname><given-names>S.M.</given-names></name>
<name><surname>Hillebrand</surname><given-names>G.H.</given-names></name>
<name><surname>Lin</surname><given-names>H.K.</given-names></name>
<name><surname>Reppart</surname><given-names>J.D.</given-names></name>
<name><surname>Stauff</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>Directed evolution reveals the mechanism of HitRS signaling transduction in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1009148</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009148</pub-id><pub-id pub-id-type="pmid">33362282</pub-id>
</element-citation></ref><ref id="B128-toxins-17-00056"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vetter</surname><given-names>S.M.</given-names></name>
<name><surname>Schlievert</surname><given-names>P.M.</given-names></name>
</person-group><article-title>The two-component system <italic toggle="yes">Bacillus</italic> respiratory response A and B (BrrA-BrrB) is a virulence factor regulator in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>7343</fpage><lpage>7352</lpage><pub-id pub-id-type="doi">10.1021/bi700184s</pub-id><pub-id pub-id-type="pmid">17536838</pub-id>
</element-citation></ref><ref id="B129-toxins-17-00056"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stauff</surname><given-names>D.L.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> HssRS signalling to HrtAB regulates haem resistance during infection</article-title><source>Mol. Microbiol.</source><year>2009</year><volume>72</volume><fpage>763</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2009.06684.x</pub-id><pub-id pub-id-type="pmid">19400785</pub-id>
</element-citation></ref><ref id="B130-toxins-17-00056"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mike</surname><given-names>L.A.</given-names></name>
<name><surname>Choby</surname><given-names>J.E.</given-names></name>
<name><surname>Brinkman</surname><given-names>P.R.</given-names></name>
<name><surname>Olive</surname><given-names>L.Q.</given-names></name>
<name><surname>Dutter</surname><given-names>B.F.</given-names></name>
<name><surname>Ivan</surname><given-names>S.J.</given-names></name>
<name><surname>Gibbs</surname><given-names>C.M.</given-names></name>
<name><surname>Sulikowski</surname><given-names>G.A.</given-names></name>
<name><surname>Stauff</surname><given-names>D.L.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Two-component system cross-regulation integrates <italic toggle="yes">Bacillus anthracis</italic> response to heme and cell envelope stress</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004044</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004044</pub-id><pub-id pub-id-type="pmid">24675902</pub-id>
</element-citation></ref><ref id="B131-toxins-17-00056"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>D.P.</given-names></name>
<name><surname>Ganova-Raeva</surname><given-names>L.</given-names></name>
<name><surname>Green</surname><given-names>B.D.</given-names></name>
<name><surname>Wilkinson</surname><given-names>S.R.</given-names></name>
<name><surname>Young</surname><given-names>M.</given-names></name>
<name><surname>Youngman</surname><given-names>P.</given-names></name>
</person-group><article-title>Characterization of spo0A homologues in diverse Bacillus and Clostridium species identifies a probable DNA-binding domain</article-title><source>Mol. Microbiol.</source><year>1994</year><volume>14</volume><fpage>411</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1994.tb02176.x</pub-id><pub-id pub-id-type="pmid">7885226</pub-id>
</element-citation></ref><ref id="B132-toxins-17-00056"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brunsing</surname><given-names>R.L.</given-names></name>
<name><surname>La Clair</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Chiang</surname><given-names>C.</given-names></name>
<name><surname>Hancock</surname><given-names>L.E.</given-names></name>
<name><surname>Perego</surname><given-names>M.</given-names></name>
<name><surname>Hoch</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Characterization of sporulation histidine kinases of <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Bacteriol.</source><year>2005</year><volume>187</volume><fpage>6972</fpage><lpage>6981</lpage><pub-id pub-id-type="doi">10.1128/JB.187.20.6972-6981.2005</pub-id><pub-id pub-id-type="pmid">16199567</pub-id>
</element-citation></ref><ref id="B133-toxins-17-00056"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stephenson</surname><given-names>K.</given-names></name>
<name><surname>Hoch</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Evolution of signalling in the sporulation phosphorelay</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>46</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.03186.x</pub-id><pub-id pub-id-type="pmid">12406209</pub-id>
</element-citation></ref><ref id="B134-toxins-17-00056"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bongiorni</surname><given-names>C.</given-names></name>
<name><surname>Stoessel</surname><given-names>R.</given-names></name>
<name><surname>Shoemaker</surname><given-names>D.</given-names></name>
<name><surname>Perego</surname><given-names>M.</given-names></name>
</person-group><article-title>Rap phosphatase of virulence plasmid pXO1 inhibits <italic toggle="yes">Bacillus anthracis</italic> sporulation</article-title><source>J. Bacteriol.</source><year>2006</year><volume>188</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1128/JB.188.2.487-498.2006</pub-id><pub-id pub-id-type="pmid">16385039</pub-id>
</element-citation></ref><ref id="B135-toxins-17-00056"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gopalani</surname><given-names>M.</given-names></name>
<name><surname>Dhiman</surname><given-names>A.</given-names></name>
<name><surname>Rahi</surname><given-names>A.</given-names></name>
<name><surname>Kandari</surname><given-names>D.</given-names></name>
<name><surname>Bhatnagar</surname><given-names>R.</given-names></name>
</person-group><article-title>Identification, Functional Characterization and Regulon Prediction of a Novel Two Component System Comprising BAS0540-BAS0541 of <italic toggle="yes">Bacillus anthracis</italic></article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0158895</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0158895</pub-id><pub-id pub-id-type="pmid">27392063</pub-id>
</element-citation></ref><ref id="B136-toxins-17-00056"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Jain</surname><given-names>K.</given-names></name>
<name><surname>Garg</surname><given-names>R.</given-names></name>
<name><surname>Malik</surname><given-names>A.</given-names></name>
<name><surname>Gulati</surname><given-names>P.</given-names></name>
<name><surname>Bhatnagar</surname><given-names>R.</given-names></name>
</person-group><article-title>Characterization of a two component system, Bas1213-1214, important for oxidative stress in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>J. Cell. Biochem.</source><year>2018</year><volume>119</volume><fpage>5761</fpage><lpage>5774</lpage><pub-id pub-id-type="doi">10.1002/jcb.26751</pub-id><pub-id pub-id-type="pmid">29537101</pub-id>
</element-citation></ref><ref id="B137-toxins-17-00056"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virmani</surname><given-names>R.</given-names></name>
<name><surname>Pradhan</surname><given-names>P.</given-names></name>
<name><surname>Joshi</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>A.L.</given-names></name>
<name><surname>Joshi</surname><given-names>H.C.</given-names></name>
<name><surname>Sajid</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>V.</given-names></name>
<name><surname>Kundu</surname><given-names>B.</given-names></name>
<name><surname>Blankenberg</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Phosphorylation-mediated regulation of the <italic toggle="yes">Bacillus anthracis</italic> phosphoglycerate mutase by the Ser/Thr protein kinase PrkC</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2023</year><volume>665</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2023.04.039</pub-id><pub-id pub-id-type="pmid">37149987</pub-id>
</element-citation></ref><ref id="B138-toxins-17-00056"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virmani</surname><given-names>R.</given-names></name>
<name><surname>Sajid</surname><given-names>A.</given-names></name>
<name><surname>Singhal</surname><given-names>A.</given-names></name>
<name><surname>Gaur</surname><given-names>M.</given-names></name>
<name><surname>Joshi</surname><given-names>J.</given-names></name>
<name><surname>Bothra</surname><given-names>A.</given-names></name>
<name><surname>Garg</surname><given-names>R.</given-names></name>
<name><surname>Misra</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>V.P.</given-names></name>
<name><surname>Molle</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>The Ser/Thr protein kinase PrkC imprints phenotypic memory in <italic toggle="yes">Bacillus anthracis</italic> spores by phosphorylating the glycolytic enzyme enolase</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>8930</fpage><lpage>8941</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.005424</pub-id><pub-id pub-id-type="pmid">30952697</pub-id>
</element-citation></ref><ref id="B139-toxins-17-00056"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arora</surname><given-names>G.</given-names></name>
<name><surname>Sajid</surname><given-names>A.</given-names></name>
<name><surname>Virmani</surname><given-names>R.</given-names></name>
<name><surname>Singhal</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>C.M.S.</given-names></name>
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Khanna</surname><given-names>T.</given-names></name>
<name><surname>Maji</surname><given-names>A.</given-names></name>
<name><surname>Misra</surname><given-names>R.</given-names></name>
<name><surname>Molle</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Ser/Thr protein kinase PrkC-mediated regulation of GroEL is critical for biofilm formation in <italic toggle="yes">Bacillus anthracis</italic></article-title><source>npj Biofilms Microbiomes</source><year>2017</year><volume>3</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1038/s41522-017-0015-4</pub-id><pub-id pub-id-type="pmid">28649408</pub-id>
</element-citation></ref><ref id="B140-toxins-17-00056"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhasmana</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Gangwal</surname><given-names>A.</given-names></name>
<name><surname>Keshavam</surname><given-names>C.C.</given-names></name>
<name><surname>Singh</surname><given-names>L.K.</given-names></name>
<name><surname>Sangwan</surname><given-names>N.</given-names></name>
<name><surname>Nashier</surname><given-names>P.</given-names></name>
<name><surname>Biswas</surname><given-names>S.</given-names></name>
<name><surname>Pomerantsev</surname><given-names>A.P.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Bacillus anthracis</italic> chain length, a virulence determinant, is regulated by membrane localized serine/threonine protein kinase PrkC</article-title><source>J. Bacteriol.</source><year>2021</year><volume>203</volume><fpage>JB.00582</fpage><pub-id pub-id-type="doi">10.1128/JB.00582-20</pub-id><pub-id pub-id-type="pmid">33753466</pub-id>
</element-citation></ref><ref id="B141-toxins-17-00056"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bem</surname><given-names>A.E.</given-names></name>
<name><surname>Velikova</surname><given-names>N.</given-names></name>
<name><surname>Pellicer</surname><given-names>M.T.</given-names></name>
<name><surname>Baarlen</surname><given-names>P.</given-names></name>
<name><surname>Marina</surname><given-names>A.</given-names></name>
<name><surname>Wells</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Bacterial histidine kinases as novel antibacterial drug targets</article-title><source>ACS Chem. Biol.</source><year>2015</year><volume>10</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1021/cb5007135</pub-id><pub-id pub-id-type="pmid">25436989</pub-id>
</element-citation></ref><ref id="B142-toxins-17-00056"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danilenko</surname><given-names>V.N.</given-names></name>
<name><surname>Osolodkin</surname><given-names>D.I.</given-names></name>
<name><surname>Lakatosh</surname><given-names>S.A.</given-names></name>
<name><surname>Preobrazhenskaya</surname><given-names>M.N.</given-names></name>
<name><surname>Shtil</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Bacterial eukaryotic type serine-threonine protein kinases: From structural biology to targeted anti-infective drug design</article-title><source>Curr. Top. Med. Chem.</source><year>2011</year><volume>11</volume><fpage>1352</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.2174/156802611795589566</pub-id><pub-id pub-id-type="pmid">21513496</pub-id>
</element-citation></ref><ref id="B143-toxins-17-00056"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kummerfeldt</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Raxibacumab: Potential role in the treatment of inhalational anthrax</article-title><source>Infect. Drug Resist.</source><year>2014</year><volume>7</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.2147/IDR.S47305</pub-id><pub-id pub-id-type="pmid">24812521</pub-id>
</element-citation></ref><ref id="B144-toxins-17-00056"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagy</surname><given-names>C.F.</given-names></name>
<name><surname>Leach</surname><given-names>T.S.</given-names></name>
<name><surname>King</surname><given-names>A.</given-names></name>
<name><surname>Guttendorf</surname><given-names>R.</given-names></name>
</person-group><article-title>Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2018</year><volume>7</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1002/cpdd.410</pub-id><pub-id pub-id-type="pmid">29125719</pub-id>
</element-citation></ref><ref id="B145-toxins-17-00056"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgopoulos</surname><given-names>A.P.</given-names></name>
<name><surname>James</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Anthrax Vaccines in the 21st Century</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>159</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12020159</pub-id><pub-id pub-id-type="pmid">38400142</pub-id>
</element-citation></ref><ref id="B146-toxins-17-00056"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modi</surname><given-names>T.</given-names></name>
<name><surname>Gervais</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>J.</given-names></name>
<name><surname>Subramaniam</surname><given-names>S.</given-names></name>
<name><surname>Thalassinos</surname><given-names>K.</given-names></name>
<name><surname>Shepherd</surname><given-names>A.</given-names></name>
</person-group><article-title>Characterization of the UK anthrax vaccine and human immunogenicity</article-title><source>Hum. Vaccine Immunother.</source><year>2021</year><volume>17</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1799668</pub-id><pub-id pub-id-type="pmid">32897798</pub-id>
</element-citation></ref><ref id="B147-toxins-17-00056"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merkel</surname><given-names>T.J.</given-names></name>
<name><surname>Perera</surname><given-names>P.Y.</given-names></name>
<name><surname>Lee</surname><given-names>G.M.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Hiroi</surname><given-names>T.</given-names></name>
<name><surname>Yokote</surname><given-names>H.</given-names></name>
<name><surname>Waldmann</surname><given-names>T.A.</given-names></name>
<name><surname>Perera</surname><given-names>L.P.</given-names></name>
</person-group><article-title>Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection</article-title><source>Hum. Vaccine Immunother.</source><year>2013</year><volume>9</volume><fpage>1841</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.4161/hv.25337</pub-id></element-citation></ref><ref id="B148-toxins-17-00056"><label>148.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><article-title>FDA Biothrax</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/biothrax" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/biothrax</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-21">(accessed on 21 November 2024)</date-in-citation></element-citation></ref><ref id="B149-toxins-17-00056"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brachman</surname><given-names>P.S.</given-names></name>
<name><surname>Gold</surname><given-names>H.</given-names></name>
<name><surname>Plotkin</surname><given-names>S.A.</given-names></name>
<name><surname>Fekety</surname><given-names>F.R.</given-names></name>
<name><surname>Werrin</surname><given-names>M.</given-names></name>
<name><surname>Ingraham</surname><given-names>N.R.</given-names></name>
</person-group><article-title>Field Evaluation of a Human Anthrax Vaccine</article-title><source>Am. J. Public Health Nations Health</source><year>1962</year><volume>52</volume><fpage>632</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.2105/AJPH.52.4.632</pub-id><pub-id pub-id-type="pmid">18017912</pub-id>
</element-citation></ref><ref id="B150-toxins-17-00056"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charlton</surname><given-names>S.</given-names></name>
<name><surname>Herbert</surname><given-names>M.</given-names></name>
<name><surname>McGlashan</surname><given-names>J.</given-names></name>
<name><surname>King</surname><given-names>A.</given-names></name>
<name><surname>Jones</surname><given-names>P.</given-names></name>
<name><surname>West</surname><given-names>K.</given-names></name>
<name><surname>Roberts</surname><given-names>A.</given-names></name>
<name><surname>Silman</surname><given-names>N.</given-names></name>
<name><surname>Marks</surname><given-names>T.</given-names></name>
<name><surname>Hudson</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A study of the physiology of <italic toggle="yes">Bacillus anthracis</italic> Sterne during manufacture of the UK acellular anthrax vaccine</article-title><source>J. Appl. Microbiol.</source><year>2007</year><volume>103</volume><fpage>1453</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2007.03391.x</pub-id><pub-id pub-id-type="pmid">17953556</pub-id>
</element-citation></ref><ref id="B151-toxins-17-00056"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shlyakhov</surname><given-names>E.N.</given-names></name>
<name><surname>Rubinstein</surname><given-names>E.</given-names></name>
</person-group><article-title>Human live anthrax vaccine in the former USSR</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><fpage>727</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)90223-2</pub-id><pub-id pub-id-type="pmid">8091851</pub-id>
</element-citation></ref><ref id="B152-toxins-17-00056"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feodorova</surname><given-names>V.A.</given-names></name>
<name><surname>Sayapina</surname><given-names>L.V.</given-names></name>
<name><surname>Corbel</surname><given-names>M.J.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
</person-group><article-title>Russian vaccines against especially dangerous bacterial pathogens</article-title><source>Emerg. Microbes Infect.</source><year>2014</year><volume>3</volume><fpage>e86</fpage><pub-id pub-id-type="doi">10.1038/emi.2014.82</pub-id><pub-id pub-id-type="pmid">26038506</pub-id>
</element-citation></ref><ref id="B153-toxins-17-00056"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahhas</surname><given-names>M.A.</given-names></name>
<name><surname>Alsenaidy</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen</article-title><source>Saudi Pharm. J.</source><year>2022</year><volume>30</volume><fpage>595</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2022.02.011</pub-id><pub-id pub-id-type="pmid">35693445</pub-id>
</element-citation></ref><ref id="B154-toxins-17-00056"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klinman</surname><given-names>D.M.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Little</surname><given-names>S.F.</given-names></name>
<name><surname>Currie</surname><given-names>D.</given-names></name>
<name><surname>Ivins</surname><given-names>B.E.</given-names></name>
</person-group><article-title>CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2881</fpage><lpage>2886</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.12.020</pub-id><pub-id pub-id-type="pmid">15246624</pub-id>
</element-citation></ref><ref id="B155-toxins-17-00056"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>M.</given-names></name>
<name><surname>Hine</surname><given-names>P.M.</given-names></name>
<name><surname>James Jackson</surname><given-names>W.</given-names></name>
<name><surname>Giri</surname><given-names>L.</given-names></name>
<name><surname>Nabors</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>526</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.07.056</pub-id><pub-id pub-id-type="pmid">16973247</pub-id>
</element-citation></ref><ref id="B156-toxins-17-00056"><label>156.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Emergent Biosolutions</collab>
</person-group><article-title>BioThrax</article-title><comment>Available online: <ext-link xlink:href="https://www.emergentbiosolutions.com/wp-content/uploads/2022/01/BioThrax-US-Prescribing-Information.pdf" ext-link-type="uri">https://www.emergentbiosolutions.com/wp-content/uploads/2022/01/BioThrax-US-Prescribing-Information.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-24">(accessed on 24 November 2024)</date-in-citation></element-citation></ref><ref id="B157-toxins-17-00056"><label>157.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Emergent Biosolutions</collab>
</person-group><article-title>CYFENDUS</article-title><comment>Available online: <ext-link xlink:href="https://www.emergentbiosolutions.com/wp-content/uploads/2024/07/CYFENDUS-Prescribing-Information-and-Patient-Information-United-States-7.pdf" ext-link-type="uri">https://www.emergentbiosolutions.com/wp-content/uploads/2024/07/CYFENDUS-Prescribing-Information-and-Patient-Information-United-States-7.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-24">(accessed on 24 November 2024)</date-in-citation></element-citation></ref><ref id="B158-toxins-17-00056"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hermanson</surname><given-names>G.</given-names></name>
<name><surname>Whitlow</surname><given-names>V.</given-names></name>
<name><surname>Parker</surname><given-names>S.</given-names></name>
<name><surname>Tonsky</surname><given-names>K.</given-names></name>
<name><surname>Rusalov</surname><given-names>D.</given-names></name>
<name><surname>Ferrari</surname><given-names>M.</given-names></name>
<name><surname>Lalor</surname><given-names>P.</given-names></name>
<name><surname>Komai</surname><given-names>M.</given-names></name>
<name><surname>Mere</surname><given-names>R.</given-names></name>
<name><surname>Bell</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>13601</fpage><lpage>13606</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405557101</pub-id><pub-id pub-id-type="pmid">15342913</pub-id>
</element-citation></ref><ref id="B159-toxins-17-00056"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McConnell</surname><given-names>M.J.</given-names></name>
<name><surname>Hanna</surname><given-names>P.C.</given-names></name>
<name><surname>Imperiale</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Adenovirus-based prime-boost immunization for rapid vaccination against anthrax</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300034</pub-id><pub-id pub-id-type="pmid">17164792</pub-id>
</element-citation></ref><ref id="B160-toxins-17-00056"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Jex</surname><given-names>E.</given-names></name>
<name><surname>Feng</surname><given-names>T.</given-names></name>
<name><surname>Sivko</surname><given-names>G.S.</given-names></name>
<name><surname>Baillie</surname><given-names>L.W.</given-names></name>
<name><surname>Goldman</surname><given-names>S.</given-names></name>
<name><surname>Van Kampen</surname><given-names>K.R.</given-names></name>
<name><surname>Tang</surname><given-names>D.C.</given-names></name>
</person-group><article-title>An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1128/CVI.00280-12</pub-id><pub-id pub-id-type="pmid">23100479</pub-id>
</element-citation></ref><ref id="B161-toxins-17-00056"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Yi</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1128/CVI.00560-13</pub-id><pub-id pub-id-type="pmid">24307239</pub-id>
</element-citation></ref><ref id="B162-toxins-17-00056"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chitlaru</surname><given-names>T.</given-names></name>
<name><surname>Israeli</surname><given-names>M.</given-names></name>
<name><surname>Rotem</surname><given-names>S.</given-names></name>
<name><surname>Elia</surname><given-names>U.</given-names></name>
<name><surname>Bar-Haim</surname><given-names>E.</given-names></name>
<name><surname>Ehrlich</surname><given-names>S.</given-names></name>
<name><surname>Cohen</surname><given-names>O.</given-names></name>
<name><surname>Shafferman</surname><given-names>A.</given-names></name>
</person-group><article-title>A novel live attenuated anthrax spore vaccine based on an acapsular <italic toggle="yes">Bacillus anthracis</italic> Sterne strain with mutations in the htrA, lef and cya genes</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>6030</fpage><lpage>6040</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.033</pub-id><pub-id pub-id-type="pmid">28342664</pub-id>
</element-citation></ref><ref id="B163-toxins-17-00056"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skoble</surname><given-names>J.</given-names></name>
<name><surname>Beaber</surname><given-names>J.W.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Lovchik</surname><given-names>J.A.</given-names></name>
<name><surname>Sower</surname><given-names>L.E.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Luckett</surname><given-names>W.</given-names></name>
<name><surname>Peterson</surname><given-names>J.W.</given-names></name>
<name><surname>Calendar</surname><given-names>R.</given-names></name>
<name><surname>Portnoy</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Killed but metabolically active <italic toggle="yes">Bacillus anthracis</italic> vaccines induce broad and protective immunity against anthrax</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>1649</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1128/IAI.00530-08</pub-id><pub-id pub-id-type="pmid">19168734</pub-id>
</element-citation></ref><ref id="B164-toxins-17-00056"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hicks</surname><given-names>C.W.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
<name><surname>Sweeney</surname><given-names>D.A.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Barochia</surname><given-names>A.</given-names></name>
<name><surname>Eichacker</surname><given-names>P.Q.</given-names></name>
</person-group><article-title>The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock</article-title><source>Toxins</source><year>2011</year><volume>3</volume><fpage>1185</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.3390/toxins3091185</pub-id><pub-id pub-id-type="pmid">22069762</pub-id>
</element-citation></ref><ref id="B165-toxins-17-00056"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>S.R.</given-names></name>
<name><surname>Willingham</surname><given-names>M.C.</given-names></name>
<name><surname>Bour</surname><given-names>S.H.</given-names></name>
<name><surname>Andreas</surname><given-names>E.A.</given-names></name>
<name><surname>Park</surname><given-names>S.K.</given-names></name>
<name><surname>Jackson</surname><given-names>C.</given-names></name>
<name><surname>Duesbery</surname><given-names>N.S.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Tang</surname><given-names>W.J.</given-names></name>
<name><surname>Frankel</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage</article-title><source>Microb. Pathog.</source><year>2008</year><volume>44</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2007.12.001</pub-id><pub-id pub-id-type="pmid">18222626</pub-id>
</element-citation></ref><ref id="B166-toxins-17-00056"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bower</surname><given-names>W.A.</given-names></name>
<name><surname>Hendricks</surname><given-names>K.</given-names></name>
<name><surname>Pillai</surname><given-names>S.</given-names></name>
<name><surname>Guarnizo</surname><given-names>J.</given-names></name>
<name><surname>Meaney-Delman</surname><given-names>D.</given-names></name>
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident</article-title><source>MMWR Recomm. Rep.</source><year>2015</year><volume>64</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6404a1</pub-id></element-citation></ref><ref id="B167-toxins-17-00056"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hart</surname><given-names>C.A.</given-names></name>
<name><surname>Beeching</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Prophylactic treatment of anthrax with antibiotics</article-title><source>BMJ</source><year>2001</year><volume>323</volume><fpage>1017</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1136/bmj.323.7320.1017</pub-id><pub-id pub-id-type="pmid">11691746</pub-id>
</element-citation></ref><ref id="B168-toxins-17-00056"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martchenko Shilman</surname><given-names>M.</given-names></name>
<name><surname>Bartolo</surname><given-names>G.</given-names></name>
<name><surname>Alameh</surname><given-names>S.</given-names></name>
<name><surname>Peterson</surname><given-names>J.W.</given-names></name>
<name><surname>Lawrence</surname><given-names>W.S.</given-names></name>
<name><surname>Peel</surname><given-names>J.E.</given-names></name>
<name><surname>Sivasubramani</surname><given-names>S.K.</given-names></name>
<name><surname>Beasley</surname><given-names>D.W.C.</given-names></name>
<name><surname>Cote</surname><given-names>C.K.</given-names></name>
<name><surname>Demons</surname><given-names>S.T.</given-names></name>
<etal/>
</person-group><article-title>In Vivo Activity of Repurposed Amodiaquine as a Host-Targeting Therapy for the Treatment of Anthrax</article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>2176</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00190</pub-id><pub-id pub-id-type="pmid">34218660</pub-id>
</element-citation></ref><ref id="B169-toxins-17-00056"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biron</surname><given-names>B.</given-names></name>
<name><surname>Beck</surname><given-names>K.</given-names></name>
<name><surname>Dyer</surname><given-names>D.</given-names></name>
<name><surname>Mattix</surname><given-names>M.</given-names></name>
<name><surname>Twenhafel</surname><given-names>N.</given-names></name>
<name><surname>Nalca</surname><given-names>A.</given-names></name>
</person-group><article-title>Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>2206</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.1128/AAC.04593-14</pub-id><pub-id pub-id-type="pmid">25645849</pub-id>
</element-citation></ref><ref id="B170-toxins-17-00056"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>A.W.</given-names></name>
<name><surname>Morrill</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Obiltoxaximab: Adding to the Treatment Arsenal for <italic toggle="yes">Bacillus anthracis</italic> Infection</article-title><source>Ann. Pharmacother.</source><year>2017</year><volume>51</volume><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1177/1060028017713029</pub-id><pub-id pub-id-type="pmid">28573869</pub-id>
</element-citation></ref><ref id="B171-toxins-17-00056"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>C.W.</given-names></name>
<name><surname>Morris</surname><given-names>S.</given-names></name>
</person-group><article-title>Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration &#x0201c;Animal Rule&#x0201d;</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><elocation-id>1320</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.01320</pub-id><pub-id pub-id-type="pmid">26648915</pub-id>
</element-citation></ref><ref id="B172-toxins-17-00056"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forino</surname><given-names>M.</given-names></name>
<name><surname>Johnson</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>T.Y.</given-names></name>
<name><surname>Rozanov</surname><given-names>D.V.</given-names></name>
<name><surname>Savinov</surname><given-names>A.Y.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Fattorusso</surname><given-names>R.</given-names></name>
<name><surname>Becattini</surname><given-names>B.</given-names></name>
<name><surname>Orry</surname><given-names>A.J.</given-names></name>
<name><surname>Jung</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Efficient synthetic inhibitors of anthrax lethal factor</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>9499</fpage><lpage>9504</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502733102</pub-id><pub-id pub-id-type="pmid">15983377</pub-id>
</element-citation></ref><ref id="B173-toxins-17-00056"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Dong</surname><given-names>D.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Cai</surname><given-names>C.</given-names></name>
<name><surname>Hou</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor</article-title><source>FEBS Lett.</source><year>2009</year><volume>583</volume><fpage>1257</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2009.03.053</pub-id><pub-id pub-id-type="pmid">19332063</pub-id>
</element-citation></ref><ref id="B174-toxins-17-00056"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Chvyrkova</surname><given-names>I.</given-names></name>
<name><surname>Terzyan</surname><given-names>S.</given-names></name>
<name><surname>Wakeham</surname><given-names>N.</given-names></name>
<name><surname>Turner</surname><given-names>R.</given-names></name>
<name><surname>Ghosh</surname><given-names>A.K.</given-names></name>
<name><surname>Zhang</surname><given-names>X.C.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
</person-group><article-title>Inhibition of anthrax lethal factor: Lability of hydroxamate as a chelating group</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>94</volume><fpage>1041</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1007/s00253-012-3893-7</pub-id><pub-id pub-id-type="pmid">22270239</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="toxins-17-00056-f001"><label>Figure 1</label><caption><p>Life cycle of <italic toggle="yes">Bacillus anthracis</italic>. MC: Mother Cell; FS: Forespore.</p></caption><graphic xlink:href="toxins-17-00056-g001" position="float"/></fig><fig position="float" id="toxins-17-00056-f002"><label>Figure 2</label><caption><p>Stages of sporulation in <italic toggle="yes">Bacillus anthracis</italic>.</p></caption><graphic xlink:href="toxins-17-00056-g002" position="float"/></fig><fig position="float" id="toxins-17-00056-f003"><label>Figure 3</label><caption><p>Transmission electron micrographs of <italic toggle="yes">Bacillus anthracis</italic> spores formed under normal growth conditions (Adapted and modified from [<xref rid="B28-toxins-17-00056" ref-type="bibr">28</xref>]). Arrows represent the different layers of a mature spore: exosporium (A), spore coat (B), cortex (C), core wall (D) and core (E).</p></caption><graphic xlink:href="toxins-17-00056-g003" position="float"/></fig><fig position="float" id="toxins-17-00056-f004"><label>Figure 4</label><caption><p>Stages of germination and outgrowth in <italic toggle="yes">Bacillus anthracis</italic>.</p></caption><graphic xlink:href="toxins-17-00056-g004" position="float"/></fig><fig position="float" id="toxins-17-00056-f005"><label>Figure 5</label><caption><p>(<bold>A</bold>) <italic toggle="yes">Bacillus anthracis</italic> cell with pXO1 and pXO2 plasmid. (<bold>B</bold>) Virulence factors encoded by pXO1 and pXO2.</p></caption><graphic xlink:href="toxins-17-00056-g005" position="float"/></fig><fig position="float" id="toxins-17-00056-f006"><label>Figure 6</label><caption><p>Schematic representation of mechanism of anthrax toxins action inside the host: (1) Binding of PA to CMG2. (2) Cleavage of N-terminal of PA (20 KDa) by furin-endoprotease. (3) Oligomerization of the cleaved part of PA (63 KDa) into ring-shaped octamer, which binds to LF and EF. (4) The internalization of the complex through clathrin-mediated endocytosis. (5) PA undergoes acidification inside the endosome and forms a narrow channel, leading to translocation of LF and EF into cytosol. (6) LF (Zn-dependent protease) acts on the MAPKK pathway, leading to disruption of host cellular pathways, while EF (calmodulin-dependent adenylyl cyclase) converts ATP into cAMP and disrupt cellular homeostasis leading to death of host. The up-arrow shows the increase in cAMP levels and down-arrow shows the disruption of MAPKK pathway.</p></caption><graphic xlink:href="toxins-17-00056-g006" position="float"/></fig><fig position="float" id="toxins-17-00056-f007"><label>Figure 7</label><caption><p>Schematic representation of role of anthrax toxin in cancer treatment.</p></caption><graphic xlink:href="toxins-17-00056-g007" position="float"/></fig><table-wrap position="float" id="toxins-17-00056-t002"><object-id pub-id-type="pii">toxins-17-00056-t002_Table 2</object-id><label>Table 2</label><caption><p>Types of AB toxin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AB Toxin</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Receptor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disulfide <break/>Bond <break/>Reduction</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphtheria <break/>Toxin<break/>(Dtx)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ProHB-EGF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elongation<break/>Factor 2 (EF-2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADP-ribosyl<break/>transferase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AB (1:1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anthrax<break/>Toxin <break/>(Atx)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TEM8, CMG2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Kinases<break/>MAPKK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EF = Adenylate<break/>Cyclase<break/>LF = Zn <break/>metalloprotease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AB<sub>7</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shiga Toxin<break/>(Stx)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gb3 glycolipid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rRna (28S)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA<break/>N- glycosidase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AB<sub>5</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YES</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholera<break/>Toxin<break/>(Ctx)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM1 <break/>ganglioside</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenylate cyclase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADP-ribosyl <break/>transferase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AB<sub>5</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YES</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudomonas <break/>aeruginosa-<break/>exotoxin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD91 (a2- macroglobulin receptor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADP ribosylation<break/>of elongation<break/>factor 2 (EF 2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis<break/>Inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td></tr></tbody></table></table-wrap></floats-group></article>